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ABSTRACT
Direct oral anticoagulants (DOACs), the thrombin inhibitor dabigatran and
the anti-Xa inhibitors rivaroxaban and apixaban are currently licensed for
thromboprophylaxis after orthopaedic surgery, in non-valvular atrial
fibrillation, and treatment of deep vein thrombosis and uncomplicated
pulmonary embolism. The drugs are easy to use, as standard dosing is
recommended and no routine monitoring of coagulation is advocated.
However, in cases of acute thrombosis or bleeding, emergency surgery, renal
or hepatic failure, overdose and suspected non-adherence, assessing
anticoagulant bioactivity is essential for safe and effective treatment.
The aims of this study were to firstly assess the effects of these DOACs in
commonly used coagulation screening tests (PT, INR and APTT) using both
spiked samples and samples collected from patients on treatment. Secondly,
the availability of specific methods for drug effect assessment, namely drug-
calibrated thrombin time (dabigatran) and anti-Xa (rivaroxaban, apixaban)
assays were assessed in surveys with European laboratories (n=86). Thirdly,
the effects of DOACs on these specific assays were explored using patient
samples. Finally, the effect of DOACs on the global coagulation assay thrombin
generation (TG) was assessed in patients using dabigatran, rivaroxaban or
apixaban.
The spiked sample laboratory survey included 73 laboratories for
dabigatran, 22 laboratories for rivaroxaban and 21 laboratories for apixaban.
The laboratories performed coagulation assays in samples spiked with varying
concentrations of the drug. A variety of different analysers and reagents were
observed, with 24 different coagulation analysers, 13 different PT reagents and
10 different APTT reagents used in the investigated laboratories. The effects of
all DOACs on INR were modest, but large reagent variability was noted in the
responses, with the Quick-type reagents being more sensitive to the effects of
dabigatran (p<0.001). In APTT, rivaroxaban and apixaban prolonged the
APTT only modestly, but with dabigatran there was a clear prolongation, albeit
the variability between laboratories was large (CVs 13-19% for all DOACs).
Only about a fourth of these (in the surveys ranging from 15-36% of the
participants) were able to provide more specific methods, TT or anti-Xa assays
for drug quantification at that time.
Dabigatran effects in patient samples were different than what was
observed in the surveys using spiked samples. We studied dabigatran effects
in 241 unselected patient samples. The effect on PT was very modest, with little
prolongation. In APTT, there was a curvilinear relationship (R2 = 0.71) with
dabigatran. However, the sensitivity effects among patients varied, with some
patients having a normal APTT at dabigatran levels up to 160 ng/mL. In the
specific assays, diluted thrombin time, ecarin clotting assay and anti-IIa assay
accurately quantified dabigatran concentrations as confirmed by mass
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spectrometry (R2 = 0.81, 0.96 and 0.90, respectively). In the RVVT and PiCT
assays, the correlations with diluted thrombin time were modest (R2 = 0.49
and 0.73, respectively). In TG, a paradoxical increase was observed in the
endogenous thrombin potential (ETP) and Peak TG, while lag time also
prolonged with increasing concentrations of dabigatran.
Rivaroxaban and apixaban effects on coagulation in patient samples were
further assessed in a well-characterised group of patients using these drugs for
thromboprophylaxis after orthopaedic surgery. In this study, a noticeable
inflammatory response after the surgery was evident, with a mean C reactive
protein (CRP) of over 100 mg/L at one week after surgery, while haemoglobin
and albumin were clearly below the reference intervals. This inflammatory
setting was also reflected by the increases in FVIII:C and fibrinogen at one
week after surgery. We observed clear differences between responses to
rivaroxaban and apixaban. Rivaroxaban peak levels were higher and trough
levels lower than with apixaban. This reflects the fact that rivaroxaban is dosed
only once daily (10 mg once daily), while apixaban twice daily (2.5 mg twice
daily), with corresponding steady state peak levels of 184 ng/mL and 135
ng/mL, respectively. It is noteworthy that the difference between these drugs
extended to responses in TG; the ETP response at peak drug levels was strong
with rivaroxaban, whereas with the trough drug levels, the TG parameters
were close to the baseline levels. With apixaban the responses were more
stable. The RVVT, used as a qualitative test, detected prolongation only at
rivaroxaban peak levels.
In conclusion, from the surveys performed we encountered large diversity
in different reagents used and assays offered among European laboratories,
with a wide variability in results. In the studies with patient samples, it became
evident that many factors other than drug concentration influence the
responses in coagulation assays and TG, which reflects the coagulation status
of the patients. In clinical practice, care and diligence is required when
assessing and interpreting the effects of DOACs on patients.
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1 INTRODUCTION
Anticoagulation is required when an individual has thromboembolism or deep
vein thrombosis (DVT). Anticoagulants affect the coagulation cascade by
diminishing feedback activation of coagulation factors, diminishing thrombin,
and subsequently, fibrin formation. This reduced thrombin formation also
supports fibrinolysis.
Novel anticoagulant drugs have emerged; the direct oral anticoagulants
(DOACs) include the direct thrombin inhibitor (DTI) dabigatran and the direct
FXa-inhibitors (FXaIs) rivaroxaban, apixaban and edoxaban. These agents
have the advantage of relatively predictable pharmacokinetics and
pharmacodynamics, making routine laboratory monitoring, as practised with
traditional vitamin K antagonist (VKA) anticoagulation unnecessary.1-4
However, to assess compliance, as well as acute situations, e.g. thrombosis,
bleeding events, surgery, hepatic or renal failure, DOAC bioactivity
measurement is crucial. DOAC concentrations can be accurately measured by
drug calibrated assays—thrombin time (TT) for DTI, anti-Xa for FXaIs.5
The availability of drug-calibrated assays is not yet widespread, and clinical
laboratories should be aware of the effects of DOACs on the coagulation assays
they are using. Some activated partial thromboplastin time (APTT) assays are
sensitive to dabigatran, whereas other APTT assays show little sensitivity.
Prothrombin time (PT) is usually not very sensitive to dabigatran effects.6 For
FXaIs, both PT and APTT are usually prolonged only with significant drug
concentrations.7,8 One must also be aware of  the potential  of  these drugs to
interfere with coagulation assays, one of the more critical assays being the
Russel's viper venom time (RVVT), commonly used as a test to screen for lupus
anticoagulant.9
Even though these drugs have predictable pharmacokinetics and
pharmacodynamics, the same dose does not apply for all patients. Renal
insufficiency is important to recognise, especially with dabigatran. In this
situation, the effective dose for stroke prevention in atrial fibrillation (AF) or
treatment of DVT should be reduced from the usual 150 mg twice daily dose to
110 mg twice daily. The prophylactic doses for all the DOACs are smaller than
the treatment dosages. Risk groups for bleeding complications include
patients with renal insufficiency, patients with a high number of comorbidities
and medications and patients over the age of 75.10 The decision on which
anticoagulant to use and at what dosage is complex and each anticoagulant
carries advantages and disadvantages. Indeed, further dose tailoring based on
the patient's risk profile might be in order.
The aim of this study was to examine the availability of laboratory tests to
measure the DOAC effects on screening tests PT and APTT in two quality
control surveys in European laboratories. The effects of dabigatran,
rivaroxaban and apixaban in patient samples were next studied using a
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comprehensive panel of coagulation tests, including global coagulation assays,
such as thrombin generation (TG). This allowed improved understanding of
the biological effects of these drugs in a real-life setting, in both unselected and
selected (in association with hip replacement surgery) patients
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2 REVIEW OF THE LITERATURE
2.1 OVERVIEW OF COAGULATION
Rapid haemostasis is needed in response to injury. The function of the
haemostatic system is traditionally modelled with Virchow’s triad.11 Three
components, namely blood, vessel wall and flow are all crucial for maintenance
of a normal haemostatic process. Disturbances in any of these components can
lead to thrombosis or bleeding. Blood coagulation occurs in three overlapping
stages: 1) primary haemostasis, 2) coagulation cascade leading to fibrin
formation and 3) fibrinolysis. For the purposes of this study, primary
haemostasis and fibrinolysis are only briefly covered, with more emphasis on
the coagulation cascade and fibrin formation, as these are the basis of most
coagulation laboratory tests.
Vascular collagen and von Willebrand factor (vWF) are crucial for
haemostasis initiation. Primary haemostasis occurs within seconds of tissue
injury,  by  platelet  activation  as  they  encounter  collagen  and  vWF  in  the
subendothelium. The platelet glycoprotein Ib-V-IX mediates binding between
platelets and vWF, and glycoprotein VI with collagen and platelets. Activated
platelets bind to one another via glycoprotein IIb/IIIa. They secrete
procoagulant factors, including factor V (FV), FXIII, calcium, thromboxane
and serotonin, which stimulate platelets further, thus amplifying the reaction.
Platelets express multiple chemokines, e.g. P-selectin and platelet factor 4,
which recruit leukocytes to initiate an inflammatory response in order to
curtail possible pathogens, promote angiogenesis and healing.12
Coagulation with insoluble fibrin as the end product has been extensively
studied with basic laboratory screening tests measuring time to formed fibrin.
Early on, it was recognised that essential components for blood coagulation
are prothrombin, fibrinogen and calcium.13 With the discovery of coagulation
factors and the crucial role of factors FVIII and FIX in haemophilias, a
coagulation cascade model was independently suggested by two groups in
1964.14,15 In the classic blood coagulation cascade model, the extrinsic pathway
is triggered by tissue factor (TF), and the intrinsic pathway is triggered by the
contact pathway and proceeds from FXII. The common part of the cascade
starts with FX, with both pathways eventually leading to conversion of
fibrinogen to fibrin in a thrombin-mediated reaction (Figure 1). The
coagulation cascade model is not physiological, but it is crucial to understand
when interpreting laboratory coagulation tests. In coagulation tests, factor
activation is based on this model.
Physiologically, blood coagulation is more complex. The coagulation
factors interact in complexes on the platelet phospholipid cell membrane.
Coagulation is divided into three stages. In the initiation phase, TF and FVII
form a complex, which activates FX and leads to small amounts of thrombin
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formation. This is rapidly counteracted by tissue factor pathway inhibitor
(TFPI). However, in the amplification phase the small amount of thrombin is
sufficient to activate platelets, vWF and FVIII, with concurrent activation of
FV, FIX and FXI. In the propagation phase, FIX complexes with FVIII to
activate an FV/FX-complex, which leads to greatly increased thrombin
formation. Thrombin forms a feedback loop perpetuating the amplification
phase to further propagate thrombin formation.16,17
Inhibitory feedback loops are required to prevent an uncontrolled
coagulation response. Both unspecific and specific natural inhibitors occur.
Alpha-2-macroglobulin is an unspecific serine protease inhibitor with a wide
array of functions. It functions as an inhibitor by trapping the protease.18
Specific inhibitors include the protein C complex and antithrombin. Protein C
is a natural anticoagulant, which inhibits FVa and FVIIIa. Protein S acts as a
cofactor for the reaction. Protein S and protein C are vitamin K dependent.19
Protein S circulates in protein-bound and free forms, with about 60% bound
to the complement inhibitor and 40% in a biologically active free form.20
Antithrombin is a specific inhibitor of many coagulation factors, most
importantly thrombin (FIIa) and activated factor X (FXa).21 The  role  of
antithrombin is crucial for the function of heparin anticoagulants, as they exert
their anticoagulant effects through antithrombin binding. The
aforementioned TFPI is an important inhibitor of the extrinsic pathway,
inhibiting the TF-FVIIa complex.22
With formation of the fibrin network, FXIII strengthens the clot by forming
crosslinks between fibrinogen D subunits. Fibrinolysis,  or  dissolving  of  the
clot, starts immediately after clot formation and is in interaction with primary
haemostasis and the coagulation cascade. Urokinase and tissue plasminogen
activator (tPA) form plasmin from plasminogen. Plasmin cleaves the fibrin
network between the molecule subunits D and E, leading to formation of fibrin
degradation products (FDPs). D dimer is a commonly measured FDP and it is
used as a marker of fibrinolysis and clot formation status. Fibrinolysis
inhibitors include plasminogen activator inhibitors 1 and 2, which inhibit
urokinase and tPA, and alpha-2-macroglobulin and alpha-2-antiplasmin,
which in turn inhibit plasmin.23
2.2 LABORATORY COAGULATION ASSAYS
Coagulation assays are among the most requested laboratory assays in the
clinical laboratory. Mostly due to the prevalence of warfarin use, the
international normalised ratio (INR) is the bulk assay. Many of the coagulation
laboratory tests are required under emergency situations, thus requiring a
rapid turnaround time and fluent stat test processing to attain satisfactory
service. The screening assays PT, INR and APTT are most frequently
performed, with more specialised assays usually utilised when there is clinical
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suspicion of a coagulation problem. Abnormalities in the screening tests
strongly suggest further investigation.
2.2.1 SCREENING TESTS PT, INR, APTT AND THROMBIN TIME
PT measures the extrinsic pathway coagulation factors VII, X, II and
sometimes, depending on the method, fibrinogen and FV (Figure 1). PT was
the first coagulation screening assay measuring the formation of fibrinogen.
Earlier, coagulation assessment was based on bleeding time.24 PT was
developed by Dr. Armand J. Quick in the 1930s. The method principle is
simple: anticoagulated blood (originally sodium oxalate was used, the current
state-of-the-art is to use sodium citrate) is mixed with thromboplastin solution
obtained from rabbit brain. Finally, calcium chloride is added and time in
seconds to formation of a blood clot is recorded. The sample volume is 1/3 of
the total volume.25 Most of the modern PT assays are based on the original
Quick method. With the use of photometers (turbidimetric principle), the
formation of first fibrin strands can be readily assessed for accurate results. In
the Nordic Countries, Benelux and Japan, the Owren method, first introduced
by Dr. Paul Owren in the 1950s, is the most commonly used PT assay. In the
Owren method, the plasma is heavily diluted to a ratio of 1:20, and fibrinogen
and FV are added to the reagent, to avoid the effect of those factors in Owren-
type PT assays.26,27 Abnormal PT results are expected in liver dysfunction—a
rapid change in PT is observed due to the short half-life of FVII of 6-7 hours.28
Most of the factors measured in the PT, i.e. FVII, FX and FII are vitamin K
dependent, as their synthesis requires vitamin K activity as a cofactor.29 PT is
consequently prolonged in vitamin K deficiency and with VKA anticoagulants
such as warfarin. Other causes for prolonged PT include FVII deficiency, other
anticoagulants such as heparin in high concentrations and consumption of
coagulation factors, in e.g. disseminated intravascular coagulation (DIC).
The PT alone has inter-laboratory variation depending on the
thromboplastin reagent used. Previously, common practice was to use a
standard preparation from which the PT was calibrated.30 Nevertheless,
different laboratories exhibited different sensitivities despite the standards
depending on the reagent and instrument used. In the 1980s, however, it was
discovered that a linear relationship exists between the PT and the effect on
PT due to a particular thromboplastin reagent or instrument. On this basis, it
was possible to establish a standard that would harmonise results between
different laboratories, the INR.31 The INR is calculated as follows:
Where ISI is the International Sensitivity Index, which accounts for the
differences in sensitivity in different thromboplastin reagents. The INR offers
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many benefits: laboratories can collaborate more easily on research as the
standardized values are comparable. Most importantly, the standardised INR
means that all warfarin patients receive the dose optimised for most effective
treatment. However, it should be noted that the ISI is calculated using plasma
samples from healthy individuals and on individuals on warfarin therapy.
Therefore, the INR can only be reliably used on warfarin patients. Monitoring
of other anticoagulants or detection of coagulation disturbances using INR is
unreliable and not recommended.
Figure 1 Extrinsic and intrinsic pathways of coagulation, with PT/INR and APTT measuring
extrinsic and intrinsic pathways, respectively. DOACs directly inhibit factor X or
thrombin, whereas vitamin K antagonists affect all the vitamin K-dependent factors
(*).
The INR target range in warfarin treatment is generally 2.0-3.0. In patients
with a mechanical heart valve, the INR treatment range is 2.5-3.5. In patients
with a high bleeding risk, e.g. previous intracranial bleed, hepatic failure or
elderly patients, an individual lower treatment range is often used. To assess
warfarin therapy in clinical studies, the time in therapeutic range (TTR)
parameter is used, where the INR is assumed to change linearly over two
measurement points with each treatment day assigned an INR value.32
APTT is another coagulation screening test. It measures the effect of factors
XII, XI, IX, VIII, X, V, II and fibrinogen (Figure 1). The method was first
described in 1953 by Dr. Robert D Langdell for the study of haemophilia.33 The
problem with the first assays was contact activation with the glass surfaces of
the test tubes, making the assay difficult to standardise. The technique was
improved by Dr. J Margolis, and further refined by Drs. Robert R Proctor and
Samuel I Rapaport. Kaolin was used as a contact activator. Calcium chloride-
activated coagulation and time to the formation of fibrin was measured.34,35
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Currently, both kaolin- and silica-based activators are in use. APTT, similar to
PT, is currently rapidly and reliably measured with the use of commercial
reagents and analysers. APTT is prolonged in haemophilias and hereditary
deficiencies of factor VIII and IX. APTT is also abnormal in liver failure, during
unfractionated heparin therapy and DIC.
TT is a derivative of the other coagulation screening assays, where
thrombin is added in excess to the reaction, so that the coagulation time is
dependent only on the conversion of fibrinogen to fibrin. TT has been used for
decades as a screening test for fibrinogen abnormalities and presence of
thrombin inhibitors (heparins and specific thrombin inhibitors).36 Fibrinogen
can also be assessed directly, using a clot-based method, from which
fibrinogen concentration is derived.37
From the screening tests PT and APTT, single factor assays can be derived.
The measurement principle involves using factor-deficient plasma in the
reagent (containing all the other coagulation factors except the one that is
measured), so that the coagulation factor in question becomes the rate-
limiting step in the reaction. Accordingly, it is possible to estimate the activity
of the factor as a percentage of normal. The factors that can be measured
depend on the factors affecting the assay, i.e., FVII, FX, FV and FII can be
measured in PT-based assays and all factors except FVII and FXIII in APTT-
based assays (Figure 1). FVIII and FIX are the most important in APTT-based
assays, being low in haemophilia, with high FVIII levels being a thrombophilic
risk factor.38,39 In addition to clot-based assays, chromogenic assays can be
used to measure single coagulation factors.
2.2.2 NATURAL ANTICOAGULANTS
As the screening assays PT, APTT and TT are rarely abnormal in a patient with
thrombophilia, other tests need to be used. Deficiencies of the natural
anticoagulants are among the most devastating thrombophilias, with highly
increased thrombotic tendency.40,41 The assessment of these factors is usually
performed as part of a thrombophilia screening panel. Antithrombin
deficiency leads to increased incidence of venous thrombi in particular.
Antithrombin activity is generally measured using a chromogenic assay using
either thrombin or factor Xa inhibition by antithrombin, with antithrombin
activity inversely proportional to the amount of chromophore measured. The
advantage of the chromogenic assay is that only active antithrombin is
measured. Antithrombin antigen can also be assessed using immunochemical
assays.42
Protein C and protein S act physiologically as a complex. Protein S is
required as a cofactor for protein C-mediated inactivation of FV and FVIII.
Protein C is usually measured based on clot activation, as chromogenic
methods can erroneously also measure some inactive protein C.43 Protein S
can also be measured using the activity measurement, but the approach is not
without problems, as erroneously low activities are sometimes observed.44 For
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this reason, in some laboratories, either total protein S antigen or only the free,
biologically active fraction of protein S is measured using an immunoassay.45
2.2.3 LUPUS ANTICOAGULANT
Antiphospholipid syndrome is a thrombophilic disorder characterised by the
development of phospholipid antibodies. The syndrome is peculiar in that,
oftentimes, the APTT is prolonged as the phospholipid antibodies bind to the
phospholipids in the reagent. This explains why patients might be erroneously
screened for bleeding tendency, even though they are actually at risk for
thrombosis.46 Lupus anticoagulant assay is a three-step assay. In the screening
assay, an APTT- or dilute RVVT-based assay is performed. If the result is
normal, no further testing is performed. If it is abnormal, a mixing study is
performed, where the test plasma is mixed with normal plasma at a ratio of
1:1, so that if there is a factor deficiency, it is corrected. If a patient is receiving
anticoagulants, the mixing study can also be abnormal. Finally, in the
confirmation assay, excess phospholipid is added, which normalises the
measurement if the prolongation is due to phospholipid antibodies. The
principle is that if the prolongation is due to an anticoagulant, the assay
remains prolonged.47
2.2.4 TESTS FOR FIBRINOLYSIS AND GENERAL COAGULATION
ACTIVITY
D dimer is one of the end products of fibrinolysis and is widely used as a
marker of general coagulation activity. The marker has a significant role in
excluding a diagnosis of venous thromboembolism (VTE). Negative D dimer
in an outpatient setting with a low risk for thrombosis excludes thrombosis
with a high likelihood of over 95%.48 In contrast, a positive D dimer does not
indicate thrombosis, as inflammation, pregnancy and advanced age are
associated with increased fibrin turnover and thus, increased D dimer levels.
Recently, it has been suggested that the cut-off values might need to be
adjusted according to patient age.49 Currently, the clinical practice is to use a
single cut-off, which can vary depending on the reagent and analyser used in
the laboratory. D dimer is usually measured with immunoassays, using
antibodies to detect the protein. Another method to measure general
coagulation activity, currently only in research use, is the prothrombin
fragments assay (F1+2), in which fragments released from FXa-activated
prothrombin are measured.50,51
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2.3 VITAMIN K ANTAGONISTS (VKAs)
In the 1920s and 1930s, veterinarians Drs. Frank W Schofield and LM
Roderick discovered that feeding spoiled hay made from the sweet clover
resulted in a haemorrhagic disease in cattle.52 The blood from the affected
animals failed to clot, but clotting could be achieved using prothrombin
preparation from unaffected animals. Clinically, the animals could be rescued
by cessation of feeding the spoiled hay followed by prompt blood
transfusion.53,54
In February 1933, a farmer in Wisconsin drove 190 miles with a dead heifer,
spoiled sweet clover fodder and uncoagulated blood from his cattle to Madison
in order to find a cure for his animals. The office of the State Veterinarian was
closed and he arrived at the Biochemistry building by chance.52 The
examination  of  the  hay  and  the  blood  prompted  research,  which  lead  to
isolation of the active compound dicoumarol from the spoiled sweet clover.55
The success led to the discovery of many new VKAs used in anticoagulation
(i.e., warfarin, phenindione, ethyl biscoumacetate, acenocoumarol,
phenprocoumon).52,56-59 Synthesis  of  warfarin  first  took  place  in  1948  –  its
name was derived from Wisconsin Alumni Research Foundation and
coumarin – WARFarin. It was discovered to be a more potent and more
rapidly acting anticoagulant than dicoumarol and its effects could be readily
counteracted with vitamin K. It was used to treat US president Dwight D
Eisenhower after a heart attack in 1955.52 Currently, warfarin is the most
widely used VKA, with acenocoumarol and phenprocoumon also used in
Europe.60,61
Warfarin, as well as the other VKAs, has great interindividual variation in
its metabolism. VKAs inhibit the vitamin K epoxide reductase complex
(VKORC), which converts vitamin K from its inactive to active form. VKAs, by
inhibiting this enzyme, diminish the synthesis of vitamin K-dependent
coagulation factors II, VII, IX and X. This leads to diminished formation of
fibrin. VKAs affect the extrinsic pathway of the coagulation (Figure 1) and
require continuous laboratory monitoring with the INR measurement. VKA
benefits include regular monitoring of INR, confirming patient adherence and
drug effect. This benefit is also a drawback. The inconvenience of INR
measurements every 4-8 weeks limits the lifestyle of the patients. VKA effects
can be counteracted by vitamin K administration. Vitamin K is recommended
with an INR of over 5.0-9.0, depending on the clinical situation. The effects of
vitamin K on coagulation factor levels, however, take several hours. In acute
bleeding, replacement of deficient coagulation factors is required and provides
immediate restoration of coagulation. For acute reversal, prothrombin
complex concentrates (PCC) are recommended. Fresh frozen plasma (FFP)
can also be used, if PCC is unavailable but use of FFP can easily lead to volume
overload.
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2.4 DIRECT ORAL ANTICOAGULANTS (DOACs)
As VKA metabolism and dosing are highly dependent on individual factors,
constant INR monitoring is required. Accordingly, agents that affect the
coagulation cascade directly provide a lucrative option for anticoagulation,
since their dose and effects are more easily predictable. DTIs include
ximelagatran (no longer used due to unexpected hepatic toxicity) and
dabigatran etexilate (Pradaxa®). FXaIs include rivaroxaban (Xarelto®),
apixaban (Eliquis®) and edoxaban (Lixiana®).
DOACs are advantageous in that no routine measurement for their effects
is required and dosing can be standardised due to predictable
pharmacokinetics and pharmacodynamics. The development timeline of the
currently available DOACs is shown in Figure 2.
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2.4.1 XIMELAGATRAN
Ximelagatran was developed by AstraZeneca and was the first DOAC to enter
the market. The active form, melagatran, showed significant variations in
absorption, so a prodrug form was synthesised. Melagatran showed
prolongation in PT, APTT and increased anti-Xa activity in both mouse models
and healthy human volunteers. No significant side effects were observed in
healthy volunteers.62 The beneficial effects of ximelagatran were shown in a
small open-label study with 12 patients with DVT or pulmonary embolism
(PE). Maximum plasma concentrations of 680 ng/mL and half-life of 4 hours
were observed.63 In a large patient study including 1900 patients, the effects
of ximelagatran were assessed in patients undergoing orthopaedic surgery.
The effects were compared with dalteparin. The protocol was to start with
subcutaneous melagatran injections, followed by oral ximelagatran once daily
with dose ranging from 8 to 24 mg. Small and transient increases in liver
enzymes alanine aminotransferase (ALT) and aspartate transaminase (AST)
were reported, but they were more common in the dalteparin group than in
the ximelagatran group.64 Subsequently, in a trial including 3500 patients with
non-valvular AF, ximelagatran showed non-inferiority to warfarin in systemic
thromboembolism, bleeding and all-cause mortality. In this study, the ALT
levels rose above three times the upper limit of normal in 1% of patients in the
warfarin group and 6% in the ximelagatran group.65 The drug was
subsequently approved for the European market, but the US Food and Drug
Administration (FDA) did not approve the drug due to the 6% of patients
developing elevated liver enzymes. It was subsequently found that there was a
potential of liver toxicity even after discontinuing the drug. Due to these
concerns, AstraZeneca withdrew ximelagatran from the market in 2006.
Ximelagatran is a cautionary tale of the potential hazards of introducing new
drugs in large patient populations.
2.4.2 DABIGATRAN
Dabigatran etexilate is a DTI developed by Boehringer Ingelheim. The
European Medicines Agency (EMA) first licensed dabigatran etexilate in 2008
for thromboprohylaxis after orthopaedic surgery. It was licensed for use in AF
in 2011 and DVT and uncomplicated PE in 2014.
Dabigatran etexilate is a prodrug with the active compound dabigatran,
which is released after hydrolysis of the drug by esterases in the liver, gut and
plasma. In healthy male volunteers, dabigatran etexilate was tolerated well
with no evidence of major bleeding at doses from 10 to 400 mg up to three
times a day for 7 days.66 At the highest dose of 400 mg three times daily,
bruising at venipuncture sites and gum bleeding did occur. In these early
studies, dabigatran was shown to consistently prolong the APTT at 8 and 12
hour dosing intervals. Renal function is essential, as 80% of dabigatran
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clearance is through the kidneys. Dabigatran etexilate was initially
administered in tablet form. However, as there was significant interindividual
variation in dose responses, a multiparticulate pellet capsule with sealed
coating was developed.1,66
In 2007, a study in healthy male volunteers with multiple dabigatran doses
(doses ranging from 100 to 400 mg three times daily) was performed. Drug
was administered after a fast and standardised meals were given over the study
period (6 days).67 Blood samples were taken 15 minutes before first drug
administration and subsequently in serial samples post-administration. Urine
samples were also collected 30 minutes before and serially after drug
administration. The dabigatran concentration was assessed by liquid
chromatography tandem mass spectrometry (LC-MS/MS). In this study,
blood samples were also collected for functional coagulation measurements
APTT, PT, TT and ecarin clotting time (ECT), using a Stago Compact (Roche
Diagnostics, Basel, Switzerland) coagulometer for the APTT and PT and a
Biomatic B10 coagulometer (Desaga, Wiesloch, Germany) for the TT and ECT.
The specific coagulation reagents used were not described. The mean
dabigatran peak concentrations were 128 ng/mL, 199 ng/mL and 303 ng/mL
for the 100 mg, 200 mg and 400 mg thrice-daily groups, respectively. The CV
was high (16-46%), depending on the concentration. The time to highest
dabigatran concentration was 1.25-1.5 hours. The half-life of dabigatran was
14-17.2 hours and again the CV was high (16-32%). The steady state of drug
metabolism was attained on day 3 with thrice-daily administration. There was
a clear dose effect of dabigatran plasma concentration of INR, APTT, TT and
ECT observed in this study. The prolongation pattern in APTT was curvilinear
above a dabigatran concentration of approximately 150 ng/mL. TT, INR and
ECT all showed a linear response. INR values, however, remained below 2.0
at concentrations below 400 ng/mL. TT was highly sensitive, with several-fold
prolongations already at levels of 100 ng/mL of dabigatran.
The safety and effectiveness of dabigatran was first studied in orthopaedic
patients. In the BISTRO I study in 2004 (Boehringer Ingelheim Study in
Thrombosis), dabigatran was assessed in 314 patients undergoing total hip
arthroplasty (THA) in a sequential dose-escalating study with dabigatran
doses 12.5 to 300 mg twice daily.66 The aim was to study bleeding events and
occurrence of thromboembolic events at particular dose levels. The safety
outcome was major bleeding and the primary efficacy outcome was VTE events
confirmed by venography. No patients developed major bleeding, but at the
highest concentration of 300 mg twice daily, there were minor bleeding
events, leading to discontinuation of this dose level. The DVT events were
lowest with the highest dabigatran dosage. The dabigatran peak level was 146
ng/mL at 150 mg twice-daily dosing. A linear correlation was observed with
prolongations of ECT and APTT and dabigatran concentration. In the BISTRO
II study in 2005, which included 2039 patients undergoing total hip or knee
replacement, patients were randomised to receive dabigatran etexilate or
enoxaparin.68 In a subgroup of 325 patients, dabigatran concentrations were
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measured preoperatively and on postoperative days 4 and 5 pre-dose and at
serial intervals 0-12 hours post-dose using LC-MS/MS. There was an observed
dose-response relationship with increased bleeding risk with increasing
dabigatran concentration, as well as an inverse relationship with DVT risk and
dabigatran concentration, suggesting a therapeutic range for dabigatran. The
steady state concentration of dabigatran was 48-271 ng/mL. The time to peak
dose was 2.3-2.9 hours at steady state. In comparison with enoxaparin,
dabigatran appeared to be more effective than enoxaparin in preventing
thrombosis, with an increase in bleeding events. Dabigatran was subsequently
licensed by the EMA in 2008 for prophylaxis of thrombosis after orthopaedic
surgery at doses of 220 mg once daily for most patients and a reduced dose of
150 mg once daily for patients with decreased renal function (creatinine
clearance of 30-50 mL/min), patients on verapamil, amiodarone, quinine and
elderly patients (over 75 years old). It is advocated, that no routine coagulation
monitoring is necessary.
In a pivotal RE-LY trial in 2009, dabigatran was assessed in the prevention
of stroke in non-valvular AF to demonstrate non-inferiority to warfarin.69 The
multi-centre study included 18113 AF patients randomised to receive blind
doses of dabigatran 110 mg twice daily, dabigatran 150 mg twice daily or
warfarin unblinded. The primary outcomes were stroke or systemic embolism
and the primary safety outcome was major bleeding. The average patient age
was approximately 71.5 years in all three study groups, with 63% being male.
Both the 110 mg and 150 mg twice-daily doses were non-inferior to warfarin
regarding stroke or systemic embolism rates at 1.53% per year, 1.11% per year
and 1.69% per year, respectively. The rates of major bleeding were 2.71% per
year, 3.11% per year and 3.36% per year with dabigatran 100 mg, dabigatran
150 mg and warfarin, respectively. The study established non-inferiority in the
clinical setting. The major limitations were lack of dabigatran concentration
measurements in the patients and the lack of reporting the warfarin arm
parameters in assessment of warfarin treatment (e.g. TTR). In a subsequent
analysis, in centres with poor-quality warfarin treatment of under 57.1% TTR,
dabigatran was safer in preventing both bleeding and thrombosis (hazard
ratio, HR 0.48-0.89). However, in a cohort with high TTR of over 72.6%, there
was no clear difference between warfarin and dabigatran (HR 0.59-1.45).
Interestingly, the TTR was a clear indicator for the quality of anticoagulation
as a whole, since in centres with high TTR, the bleeding and thromboembolism
incidence was also lower in the dabigatran groups.70 Dabigatran was approved
for treatment of non-valvular AF in 2011 with 150 mg twice-daily dosing,
except for patients over the age of 80 and patients on verapamil, where the
recommended dose is 110 mg twice daily. For patients 75 to 80 years old,
patients with moderate renal insufficiency, patients with gastritis, esophagitis
or reflux disease and patients with increased bleeding risk, individual risks
need to be taken into account. These patients should use either 150 mg or 110
mg twice-daily dosing, dependent on the individual assessment. However,
compared to dabigatran, warfarin was shown to be superior in patients with
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artificial mechanical heart valve, and the study was terminated due to ethical
reasons as there was a clear increase in risk with dabigatran for thromboses.71
In the RE-COVER trial in 2009, dabigatran was compared to warfarin in
the treatment of DVT after an initial parenteral anticoagulation therapy.72 The
dabigatran dose was 150 mg twice daily. In this double-blind multi-centre
study, 2539 patients experiencing DVT or PE were recruited, with a sample
size of 1274 in dabigatran and 1265 in the warfarin group. The majority (90%)
of patients were on low molecular weight heparin (LMWH) treatment before
initiation of the study group, with the remainder on unfractionated heparin or
fondaparinux. The TTR for INR was 60%. 30 patients (dabigatran group) and
27 patients (warfarin group) had thromboembolic events. Dabigatran was
non-inferior to warfarin in terms of efficacy. 20 patients (dabigatran group)
and 24 patients (warfarin group) had major bleeding episodes. Thus,
dabigatran was non-inferior in terms of adverse effects. Dabigatran was
approved for the treatment of DVT and uncomplicated PE in 2014, with the
same dosage as with AF.
Information on dabigatran effects in real-life patient population, i.e.
patients not on randomised controlled trials has emerged. In a recent meta-
analysis comprising 700000 dabigatran patients, dabigatran had a favourable
profile of stroke incidence (HR 0.86, 95% CI 0.74-0.99) and major bleeding
rate (HR 0.79, 95% CI 0.69-0.89) compared to warfarin. Dabigatran
adherence has been shown to be significantly lower in real-life settings than in
the randomised controlled trials. In a New Zealand study, 70% of patients
continued dabigatran treatment at 8 months after initiation. The primary
reasons for discontinuation were drug side effects (particularly dyspepsia).73
More encouragingly, in a recent Danish cohort study, dabigatran adherence
was 83.9% measured as the proportion of days covered for patients at one year
of treatment, after excluding the patients discontinuing treatment during that
first year. It seems that adherence is good if the patients do not encounter
severe side effects.74 In the Dresden DOAC register study, discontinuation
rates with dabigatran were similar to that of warfarin (approximately 25%).75
2.4.3 RIVAROXABAN
Rivaroxaban was developed by Bayer and is the first FXaI in its class. The EMA
licensed rivaroxaban for thromboprophylaxis after orthopaedic surgery in
2008, for thromboprophylaxis of non-valvular AF and treatment of DVT in
2011, for treatment of PE in 2012 and for thromboprophylaxis in acute
coronary syndrome in conjunction with acetylsalicylic acid (ASA) alone or ASA
and ticagrelol or clopidogrel in 2013.
In a 2005 study, rivaroxaban was shown to be safe and well-tolerated after
a  single  dose  in  healthy  male  volunteers  (dose  ranging  5  to  80  mg).  Drug
concentration was measured with LC-MS/MS and functional drug effects were
assessed with the coagulation assays anti-Xa inhibition, PT and APTT, among
others. At the 20 mg dose, rivaroxaban reached a concentration of 173 ng/mL
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with a time to highest concentration of 1.5 hours and half-life of 12.4 hours.
The coagulation assay anti-Xa inhibition showed a curvilinear response with
increasing rivaroxaban concentrations, whereas Quick PT showed a linear
response. There were no adverse effects reported with the drug.2 In another
study, with multiple doses of rivaroxaban ranging from 5 mg once daily to 30
mg twice daily, healthy male volunteers were given the drug for four days, with
monitoring of vital signs until 12 days and a full physical examination at the
end of the study. Concentration was analysed by LC-MS/MS and coagulation
function with anti-Xa inhibition, PT and APTT, among others. The steady-
state drug concentrations reached a maximum of 158 ng/mL for the 10 mg
twice-daily dosing, and the time to highest concentration was 3 hours and the
half-life was 8 hours. While one patient had elevated ALT levels while on
rivaroxaban, ALT elevations were also observed in the placebo group. In the
coagulation assays, the response was again concentration dependent, being
curvilinear in the anti-Xa inhibition assay and linear in the PT assay.76
In a phase II study with approximately 800 patients conducted in 2006,
rivaroxaban was evaluated for thromboprophylaxis of patients with THA in
both multiple-dose daily and single-dose daily regimens. In both cases,
rivaroxaban at multiple doses was compared to enoxaparin 40 mg daily.
Rivaroxaban performed favourably, particularly at the 10 mg once-daily
dosing, where the risk of composite end point events including DVT, PE, and
all-cause mortality was lowest (10.6% risk with rivaroxaban and 25.2% risk
with enoxaparin, with a bleeding risk of 0.7% and 1.9%, respectively).77,78 In a
2008 phase III trial with 4500 patients, rivaroxaban 10 mg once daily was
compared to enoxaparin 40 mg daily. Rivaroxaban achieved a statistically
significant risk reduction in major venous thromboembolism of 1.7%, with
bleeding rates similar to enoxaparin. It was concluded that rivaroxaban is as
safe and more effective than enoxaparin in this setting. There were no drug
concentration measurements.79 The EMA licensed rivaroxaban in 2008 for
thromboprophylaxis after orthopaedic surgery at 10 mg once daily dosing.
There is no dose reduction protocol, but caution should be exercised when
prescribing to patients with renal impairment.
A major breakthrough for rivaroxaban use was the 2011 phase III
randomised study ROCKET-AF, which compared rivaroxaban with warfarin
in patients with non-valvular AF.80 The study included 14000 patients. The
INR was measured using a point-of-care (POC) coagulometer Alere INRatio®.
Rivaroxaban was non-inferior to warfarin, with the primary endpoint of stroke
and systemic embolism occurring in 1.7% per year in the rivaroxaban group
and 2.2% per year in the warfarin group. Bleeding rates of 14.9% per year
(rivaroxaban group) and 14.5% per year (warfarin group) were observed. It
was concluded that rivaroxaban is at least as effective as warfarin in this
setting. There were no drug concentration measurements. In a subsequent
analysis comparing different centre TTRs, it was observed that the trend
favouring rivaroxaban was present in all of the different TTR groups, but even
greater when there was poor TTR control. Again, the centres with high TTR
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also had lower rates of bleeding or thrombosis in the rivaroxaban group,
suggesting better overall patient management.81 In December 2014, the FDA
issued a recall of Alere INRatio® coagulometers, raising doubts about the
accuracy of the results in the ROCKET-AF trial. In re-analyses of the data, it
was shown that the original conclusions are still valid. The EMA and FDA have
reviewed these data and concluded that there exists no reason to change the
original recommendation to license the drug for thromboprophylaxis in AF
patients, originally granted in 2011.82 The  dose  is  20  mg  once  daily,  with  a
reduced 15 mg daily dose for patients with a creatinine clearance of 30-49
mL/min.
Rivaroxaban in DVT treatment was also studied in a phase III trial
including 3500 patients conducted in 2010.83 Rivaroxaban was started at 15
mg  twice  daily  for  3  weeks,  after  which  the  dose  was  20  mg  once  daily
compared to the standard therapy of enoxaparin followed by the VKAs
warfarin or acenocoumarol. The efficacy of rivaroxaban was non-inferior, with
an event rate of 2.1% (rivaroxaban) and 3.0% (VKAs) and identical bleeding
rates (8.1%) in both groups. In this study, the INR was measured by a central
laboratory, so there was no issue with POC coagulometer. In a subsequent
trial, rivaroxaban also performed favourably against VKA in the treatment of
PE, with the primary efficacy outcome occurring in 2.1% (rivaroxaban) and
1.8% (standard therapy). The bleeding risk was 10.3% (rivaroxaban) and 11.4%
(standard treatment).84 As the exclusion criteria included fibrinolytic
treatment and hemodynamic instability, the results can only be generalised to
uncomplicated PE. Neither of the trials included drug concentration
measurements. The EMA licensed rivaroxaban for treatment of DVT in 2011
and uncomplicated PE in 2012 with a dosage of 15 mg twice daily for 3 weeks
and subsequently 20 mg once daily. In a subsequent Magellan trial,
rivaroxaban was non-inferior to enoxaparin for prevention of VTE in medically
ill patients, but had increased risk of bleeding.85
There are registry-based studies assessing the effects of rivaroxaban in real-
life settings. In the Dresden NOAC registry study, rivaroxaban was found to
have comparable rates of thromboembolism (2.0/100 patient-years)
compared to the ROCKET-AF study. The major bleeding rate was also
acceptable (3.0/100 patient-years). The thrombosis and also bleeding rates
were higher when the 15 mg daily dose was used, probably due to the lower
dose used in a patient population with a higher general bleeding risk.86
Rivaroxaban adherence was reported to be relatively better than with
dabigatran and warfarin, with approximately 80% of patients persisting with
treatment. This might be due to the different side-effect profile of rivaroxaban,
i.e., dyspepsia is less common than with dabigatran.86,87
2.4.4 APIXABAN
Apixaban, developed by Pfizer, is the second FXaI to reach the market. It was
licensed by the EMA in 2011 for thromboprophylaxis in patients with hip or
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knee replacement, in 2012 for thromboprophylaxis of AF and in 2014 for DVT
and PE treatment.
Apixaban was found to be a potent inhibitor of FXa using models based on
spiked samples published in 2007.88,89 In a study using radiolabelled apixaban
after a single 20 mg dose of the drug in male healthy volunteers, apixaban
metabolism was found to be approximately 15 to 30% through the renal route
(captured radioactivity in urine). Apixaban concentrations were measured
using LC-MS/MS, and apixaban radioactivity reached the highest value of 509
ng-Eq/mL with a time to highest concentration of 1 hour and a half-life of 13
hours.3 The apixaban summary of product characteristics states that the
expected concentrations are 171 ng/mL at maximum and 103 ng/mL at
minimum with a 5 mg twice-daily dose.90
In 2007, apixaban was shown to be as effective as enoxaparin and warfarin
in thromboprophylaxis after knee replacement surgery.91 The study comprised
1238 patients, with patients experiencing the primary end point of venous
thromboembolism and all-cause mortality with the most benefit at the 2.5 mg
twice-daily dose, rate of 9.0%, compared with 15.6% (enoxaparin) and 16.6%
(warfarin). There was a relative risk reduction of 21 to 69% compared to
enoxaparin. There was not a single major bleeding event at the 2.5 mg twice-
daily dose; this was not observed in the enoxaparin and warfarin groups either.
When all bleeding events (including minor) were analysed, the rates were 3%
(apixaban 2.5 mg twice daily) and 5% (enoxaparin and warfarin). It was thus
concluded that apixaban is at least as good as standard prophylaxis in this
indication and that the 2.5 mg twice-daily dose seemed to outperform the
others in terms of efficacy. However, as the bleeding events were few and no
major bleeding events were recorded, the data was not sufficient to make any
safety conclusions. No apixaban concentration measurements were included.
In a subsequent 2010 study, similar effects were shown in a study of 5500 hip
replacement patients using apixaban 2.5 mg twice daily compared to
enoxaparin 40 mg once daily.92 The primary efficacy endpoint, thrombosis,
occurred in 1.4% (apixaban group) and 3.9% (enoxaparin group). The
composite endpoint of major and clinically relevant bleeding occurred in 4.8%
(apixaban group) and 5.0% (enoxaparin group). It was therefore shown that
apixaban is associated with fewer thrombosis events with similar rates of
bleeding as enoxaparin. Apixaban was licensed by the EMA in 2011 for
thromboprohylaxis after orthopaedic surgery at a dose of 2.5 mg twice daily.
A major finding facilitating widespread apixaban use is the 2011
ARISTOTLE study on apixaban effects in AF.93 In a large study comprising
18000 patients with non-valvular AF, apixaban performed favourably in
comparison with warfarin. The apixaban dose used was 5 mg twice daily. The
rate of thrombotic outcome was 1.3% per year (apixaban) and 1.6% per year
(warfarin). The major bleeding rate was 2.1% per year (apixaban) and 3.1% per
year (warfarin). The TTR for warfarin treatment had a median of 66% and
mean of 62%. It was concluded that apixaban was superior to warfarin in
thromboprophylaxis in patients with non-valvular AF. The effect was similar
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in centres with different levels of TTR, with HRs for stroke (range 0.73-0.91)
and bleeding (range 0.50-0.75) for centre TTR levels from 25-60% and 71-
83%, respectively. Again the event rates were slightly lower in centres with a
good TTR control.94 Another study investigated potential apixaban use instead
of ASA when VKA was considered unsuitable. There was a clear benefit with
apixaban (dose 5 mg twice daily) in comparison to ASA (dose 81-324 mg daily),
with thromboembolic rates of 1.6% per year (apixaban) and 3.7% per year
(ASA). Major bleeding was 1.4% per year (apixaban) and 1.2% per year (ASA).
These results established apixaban as a suitable alternative with improved
outcome in comparison to ASA.95 The EMA licensed apixaban in 2012 for
thromboprophylaxis in AF, with a standard dose of 5 mg twice daily. A reduced
dose of 2.5 mg twice daily is recommended for patients with at least two of the
following characteristics: age over 80 years, weight below 60 kg and serum
creatinine over 133 μmol/L.
Apixaban in DVT showed a favourable profile in a phase II trial in 2008.96
In a phase III trial on 5500 patients in 2013, apixaban was shown to be
noninferior to conventional treatment using enoxaparin followed by warfarin.
The apixaban dose was 10 mg twice daily for 7 days, followed by 5 mg twice
daily for 6 months. The thromboembolic rate was 2.3% (apixaban) and 2.7%
(conventional therapy). Major bleeding was observed in 0.6% (apixaban) and
1.8% (conventional therapy). Apixaban proved to be noninferior in terms of
efficacy and superior in terms of bleeding risk.97 The EMA licensed apixaban
in 2014 for treatment of DVT and uncomplicated PE with a dose of 10 mg twice
daily for 7 days, followed by 5 mg twice daily.
2.4.5 EDOXABAN
Edoxaban is a FXaI developed by Daichii Sankyo. The EMA licensed edoxaban
in 2015 for thromboprophylaxis in AF and treatment of DVT and PE.
Edoxaban was found to be safe in animal studies in 2008.98 In healthy
human volunteers in a 2010 study, it had peak concentrations 302 ng/mL after
a single administration of the 60 mg dose, with time to peak concentration of
1 hour and a half-life of 8 hours.4 It was subsequently shown to be noninferior
to warfarin in thromboprophylaxis in AF and DVT and PE, and was licensed
by the EMA in these indications in 2015.99-101 The standard dose is 60 mg once
daily, with a reduced dose of 30 mg once daily in the very elderly and in
patients with a reduced creatinine clearance of 15-30 mL/min. Edoxaban
effects on coagulation were not assessed in this thesis, and it will not be further
discussed.
2.4.6 DOAC ANTIDOTES
If a patient experiences a serious bleed while on DOAC treatment, first the
drug is discontinued. DOAC drugs have half-lives of approximately 10-15 h, in
a patient with normal liver and renal function.102 In case of serious bleeding,
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non-specific reversal agents recombinant FVII or PCC are used.103 A specific
antidote, however, enables rapid reversal of anticoagulant effect without the
considerable risk of thrombosis, the disadvantage of the non-specific agents.
For dabigatran, a humanised monoclonal antibody fragment idarucizumab is
currently available. Idarucizumab binds to and inactivates dabigatran. It
normalises abnormal APTT and PT in dabigatran-treated patients.
Idarucizumab was licensed for emergency reversal of dabigatran effects by the
EMA in 2015. For rivaroxaban and apixaban, a specific antidote, andexanet
alfa, is currently under development. Andexanet alfa mimics FXa, binding the
inhibitors, and may be a potential universal antidote for FXa inhibitors. It has
been shown to normalise anti-Xa and TG in rivaroxaban- and apixaban-
treated patients.103
2.5 LABORATORY MONITORING OF DOACs
2.5.1 WHEN TO MONITOR
The consensus among experts is that no routine coagulation monitoring is
needed with DOACs. However, at extremes of body weight, the very elderly, in
cases of suspected non-adherence, renal or hepatic failure, acute thrombosis
or bleeding and emergency surgery, laboratory testing for anticoagulant effect
is recommended.5,10, 104 When assessing renal function, one must bear in mind
that in the original studies of DOACs, renal function was assessed with
creatinine clearance. Numerically, creatinine clearance is similar, but not
equal to the estimated glomerular filtration rate (GFR), which is commonly
used to assess kidney function. GFR is an estimate calculated from plasma
creatinine level.105 Generally, also in the elderly population (over 75 years old),
DOACs have shown at least non-inferiority and sometimes superiority in
terms of efficacy with similar rates of bleeding. However, with declining renal
function the risk for bleeding complications increases.106,107 Extremes of body
weight are likely to affect anticoagulant response. Dabigatran is lipophilic and
has a very large volume of distribution, while rivaroxaban and especially
apixaban have smaller volumes of distribution. In principle, the
pharmacodynamics studies favour one-dose-for-all protocols, since at steady
state the differences between individuals of different weight are smaller.108-110
However, plasma concentrations might be affected at the extremes of BMI.111
Dabigatran is the only DOAC that is hemodialysable, with a high volume of
distribution causing a rebound effect in concentration if haemodialysis is
ended prematurely.112 Renal function is of crucial importance especially with
dabigatran, due to dabigatran metabolising primarily (85%) through the renal
route.113 For DOAC assessment in cases of acute thrombosis, bleeding or
before surgery, the key components are time of the last drug intake, renal
function and functional measurement of DOAC concentration.
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2.5.2 PT AND APTT
The coagulation screening tests PT and APTT are widely available in clinical
chemistry laboratories, with short turnaround times facilitating stat
measurements and establishing a 24-hour service. They are well known among
clinicians prescribing anticoagulants, and INR (used to monitor warfarin) is a
test of choice for patients with bleeding risk.
Unfortunately, for the DOACs, coagulation assessment is not as simple as
measuring PT and APTT. In the early pharmacokinetic and pharmacodynamic
trials, rivaroxaban and dabigatran have shown a linear response of PT values
with increasing concentrations. APTT showed a curvilinear response with
relatively high sensitivity for dabigatran.67,76 Further experiments with in vitro
spiking of DOACs have shown variable responses using different reagents for
the PT and APTT.6,114-117 INR, while standardised for VKA treatment, cannot
be used to measure the effects of DOACs. Accordingly, it is difficult to use PT
and APTT in clinical practice, as local laboratories should examine the effects
of DOACs on the assays they are using. Apixaban is especially problematic,
since both PT and APTT usually remain within the reference interval at
treatment levels, with levels above 700 ng/mL required to double the values.8
In addition, the effects observed using spiked samples cannot be generalised
to patient samples. Typically, in actual patient populations, the effects are
similar but express even greater variation between reagents.9,118-120 However,
most of the studies on the effects of DOACs on these assays have been
performed using in vitro spiking.
2.5.3 SPECIFIC COAGULATION ASSAYS
For the DTI dabigatran, laboratory assays mostly depending on thrombin
activation seem to be suitable alternatives for activity measurement. Indeed,
TT is very sensitive to the effects of dabigatran. The problem with the test is
that the upper limit of measurement is exceeded already at low dabigatran
concentrations.121 A more specific assay, diluted thrombin time (dTT), is
commercially available in Europe. In dTT, the assay is diluted with reference
plasma that can be specifically calibrated to quantify dabigatran (Hemoclot
Thrombin Inhibitors® assay).122 While the result is expressed as dabigatran
concentration, it should be noted that what is actually measured is fibrin
formation in time, instead of the absolute concentrations. The functional
concentration, which might be higher or lower than the actual plasma
concentration, depends on the clinical situation.
Other assays that are generally not in use in routine coagulation
laboratories can be used to measure dabigatran effects. The ecarin clotting
assay (ECA) is a chromogenic assay derived from ECT, in which a chromogenic
substrate instead of clotting time (with fibrin formation) is measured. The
substrate is cleaved by meizothrombin, which has biologically similar effects
to thrombin.123,124 ECA can measure the effects of DTIs, as shown in 2003 for
hirudin, and later also for dabigatran.104,125,126 Another assay that can be used
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is the anti-IIa assay, which detects thrombin inhibition with the use of a
specific chromophore (paranitroaniline) and known amounts of added
thrombin. The assay is used during unfractionated heparin therapy, but also
has the potential to measure thrombin inhibitors, such as dabigatran.127,128
While the FXaIs apixaban and rivaroxaban affect routine anti-Xa results,
the problem lies with the LMWH-calibration of the routine assay, rendering
direct assumptions about DOAC concentrations unreliable. However, the anti-
Xa assay can be calibrated with known rivaroxaban and apixaban
concentrations to establish functional concentrations of these drugs.114,115,129
Another potential assay for DOAC measurement is the dilute RVVT, which
uses snake venom from Russel’s viper, a snake native to India. Native Russel’s
viper venom activates both factor V and factor X. Some commercial
preparations use the native venom, and some use only the factor X activating
RVV-X, which is more specific to factor X inhibition.130 As previously
discussed, the RVVT assay is commonly used in coagulation laboratories for
the detection of lupus anticoagulant.131 It has the potential to detect both
thrombin and FXa inhibitors.104 In a recent study, RVVT was prolonged with
increasing dabigatran and rivaroxaban concentrations, while the type of
DOAC (FXa or thrombin inhibition) could not be elucidated.132
The prothrombinase-induced clotting time (PiCT) has been assessed for
monitoring of thrombin inhibitors shortly after its introduction. PiCT is also
based on Russel’s viper venom, but utilising the compound activating FVa, and
with a defined amount of added FXa.133-135 PiCT has recently been studied for
measurement of dabigatran, but also rivaroxaban and apixaban, with clear
prolongations in spiked samples.116,136,137 The one-step protocol, without the
standard 180-second incubation after activator reagent (but before calcium
reagent addition), is recommended for rivaroxaban assessment. The standard
approach seems insensitive to low rivaroxaban concentrations. Instead, a
modified approach without incubation period is recommended.138
2.5.4 MASS SPECTROMETRY
Mass spectrometry is the gold standard for drug concentration measurements.
Its advantages are that it is based on the molecular mass and chemical
properties of the drug and has the potential to measure any molecule,
regardless of function. To achieve this specificity, substances need to be
introduced in the mass spectrometer in as pure a form as possible to enable
detection of the desired substance at low levels, which would otherwise
disappear in the background noise. To enable any meaningful mass
spectrometry findings, chromatography is initially used to separate the
compounds. In chromatography, a stationary phase binds to the substances
introduced in the mobile phase at different strengths based on the chemical
composition of the substance. Different substances pass through the
stationary phase at different time intervals, so each substance has a specific
retention time. The stationary phase can be gas, solid or liquid. High-
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performance liquid chromatography (HPLC) is commonly used in clinical
laboratories.139
HPLC used as a separator technique before mass spectrometry enables only
relatively pure substances to enter the mass spectrometer. In the mass
spectrometer, molecules are detected based on their mass-charge ratio (m/z).
Substances entering the device are first ionised using e.g. heat or an electrical
field. The ions are then accelerated in an electrical field, and the time to strike
the detector is based on their mass-charge ratio (time-of-flight mass
spectrometry). To gain higher specificity with a lower background signal,
tandem mass spectrometry is often used. In this method, compounds of
specific mass-charge ratio are firstly selected with a quadrupole mass
spectrometer, where only the specific compound can pass through. These ions
are then accelerated again, and collided with an inert gas molecule (often
nitrogen, argon or xenon). The molecule subsequently fragments based on its
chemical properties and the fragments strike the detector. With this method,
molecules having the same retention time and mass-charge ratio can be
separated. The result is a highly specific and sensitive assay, able to reliably
determine drug concentrations at the 1 ng/mL level. With selective reaction
monitoring, the reaction can be further sensitised to include only the molecule
with the specific fragmentation pattern. This comes at the expense of
potentially not detecting other molecules, but is highly specific to the molecule
studied.140
LC-MS/MS to measure DOACs was validated early in the drug
development process and used in pharmacokinetic studies to assess
concentrations.3,67,76 Several groups have set up mass spectrometry methods
to enable comparison of coagulation assays and functional concentrations to
the actual plasma concentration, with very low limits of detection at
approximately 1 ng/mL.137,141-144
Mass spectrometry remains the gold standard for DOAC concentration
measurement. The challenges with the method are the high technical skill and
expertise required to set up and maintain the assay.145 University hospitals and
other large centres will have the facilities to do these assays, but longer
turnaround times than the routine coagulation assays are expected.
Furthermore, the functional assay might actually give a more accurate overall
situation regarding patient care, as other pro- or anticoagulant factors present
might be reflected in the data obtained with these assays. The strength of mass
spectrometry is the ability to detect very low drug concentrations, though the
clinical significance of this is debatable.
2.5.5 THROMBIN GENERATION
As opposed to the coagulation screening tests PT, APTT and TT, where the
reaction is stopped at the formation of the first fibrin strands, TG assays
measure the entire spectrum of thrombin formation. This includes not only
the initiation phase, but also the propagation and amplification of coagulation.
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The principle of TG measurement is simple. In a solution containing
fibrinogen, the amount of thrombin is related to clotting time. When
calibration is done with known amounts of added thrombin, the amount of
thrombin in the unknown sample can then be deduced from the clotting time.
In blood samples, when samples are taken from the plasma aliquot at serial
time intervals, the TG curve as clotting progresses can be obtained.146
However, this is a highly laborious process demanding approximately 1 hour
per sample analysis time of a skilled laboratory technician. A great innovation
was the use of a fluorogenic substrate, which releases a fluorophore after
activation by thrombin. The fluorophore is longer lasting and enables
measurement of thrombin formation using a fluorometer. The measurement
is done on a well plate in parallel with a calibrator. The alpha-2-
macroglobulin-thrombin complex is used as a calibrator to provide a constant
thrombin-like activity, i.e. a fluorescence signal. The TG is then calculated
from the fluorescence signal corrected with the calibrator signal. This can be
done in a semi-automated fashion, using the Calibrated Automated
Thrombogram® (CAT) assay. The acquired parameters include lag time, i.e.
time to the start of thrombin formation, time to peak, i.e. time when maximum
concentration of thrombin is reached, peak thrombin concentration (Peak)
and endogenous thrombin potential (ETP), which is the area under the curve,
reflecting the total amount of thrombin formed. The assay generally takes
approximately 1 hour, of which only a small proportion is hands-on time. The
drawback is that platelet-rich or platelet-poor plasma needs to be prepared.147
Recently, a new method was developed using whole blood, but most of the
research so far has been performed using the plasma-based assay.148
Diminished TG is seen in haemophilia; lower TG associated with a more
severe bleeding phenotype.149 Increased TG is seen in thrombophilia, and it
has even been proposed that increased TG induces a risk of venous
thrombosis, regardless of the cause.150,151 Vice versa, in a prospective cohort
study, it was observed that after discontinuation of anticoagulation therapy,
patients with lower TG have a significantly smaller risk of recurrence.152
Furthermore, consistent with the prothrombotic state in normal pregnancy,
TG parameters were increased significantly according to gestational weeks in
healthy women.153
With the DOACs, the expected effect on TG is diminished Peak and ETP
with prolonged lag time. This has been shown in studies with in vitro spiking
of pooled plasma and also in some studies including patient samples.154-156
2.5.6 POINT-OF-CARE ASSAYS
POC assays are increasingly used to monitor a patient’s coagulation status on-
site. They are frequently used in emergency rooms when rapid assessment of
coagulation status is vital, e.g. when considering ischemic stroke thrombolysis
or emergency surgery. They also offer access to coagulation tests in remote
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locations, where the cost of a laboratory haematology analyser might be
excessive.
POC coagulation assays generally use whole blood instead of plasma. The
sample is added directly to the measurement strip or cuvette, so anticoagulant
use is not necessary upon immediate processing. No sample dilutions take
place either, as with standard PT and APTT protocol. The dilution factor is
probably the key to differences of the behaviour of POC coagulometers and
central laboratory assays.
With DOACs, it was observed first with dabigatran that the POC INR can
be significantly prolonged. In a patient case report, a 59-year-old woman who
had recently switched from warfarin to dabigatran 150 mg twice daily had a
point-of-care INR of 7.2 (with a Hemochron Jr. Signature+® device,
International Technidyne Corporation) and a central lab INR of 1.6. In another
patient, a 52-year-old man, a POC INR of 1.6 was observed 16 hours after a
single dose of dabigatran.157 In a study of whole blood from healthy volunteers
spiked with dabigatran, a POC INR (measured with a Hemochron Jr.
Signature+® device) was increased from 1.7 to 4.0 with concentrations of
approximate trough to peak levels of dabigatran from 60-275 ng/mL. The
central lab recorded an INR increase from 1.1 to 1.5.158 In actual patients
treated with rivaroxaban or dabigatran, the same phenomenon was observed,
with a PT prolongation in whole-blood measurement of 65%.159 One
coagulometer (Coaguchek XS Pro®, Roche Diagnostics) showed an almost
linear correlation of rivaroxaban (R=0.82), but was less specific for apixaban
and had no correlation with dabigatran.160 One must realise that the findings
are not generalizable to all POC assays, but must always be interpreted only in
the context that they were performed. However, if a laboratory supplies a
specific POC analyser e.g. at the emergency department and local studies were
performed, it might be possible in the future to use the POC assays as a
qualitative test to detect some of the DOACs.
2.5.7 INTERFERENCES OF DOACS ON COAGULATION ASSAYS
DOACs can interfere with many commonly used coagulation assays albeit the
abnormal assay result may refer to functional impairment anyway. Although
APTT and PT as methods to test the agents are unreliable, the drugs can
interfere with factor assays based on these measurements. Indeed, APTT-
based factor assays in particular might show erroneously low results.
However, PT-based assays might also be modestly affected with large
concentrations of the drug.
Some fibrinogen assays show diminished responses when dabigatran is
present, leading to underestimation of fibrinogen. Dabigatran can also
overestimate antithrombin activity in thrombin-based assays, potentially
leading to a deficiency state characterised as normal. In APTT-based assays,
dabigatran also showed erroneously high APC resistance ratios, which might
make heterozygous factor V Leiden patients appear normal.161 Rivaroxaban
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and apixaban have been shown to interfere with protein S activity and FXa-
based antithrombin activity. Also, as previously mentioned, the effect of FXa
inhibitors to RVVT is pronounced and might cause a false suspicion of lupus
anticoagulant.9
In light of these findings, it is critical to know the presence of a DOAC also
when interpreting thrombophilia tests. Very often the patients have started
anticoagulation or were already on anticoagulation therapy before the sample
was collected. Care should be taken when interpreting the results with a DOAC
present. Even though the lupus anticoagulant confirmation test should limit
the interference with anticoagulants, a substantial, 20-40% false positive rate
with DOACs present exists.162 As the use of DOACs is becoming widespread
and experience has accumulated, the limitations for interpretations can be
better appreciated, analogous to the well-known interferences of warfarin and
heparins. Studies on international forums are needed, as well as local testing
with the specific assays to aid in their interpretation. The problems with one
assay might be surmountable by choosing an assay with different
methodology. This was shown by the recent study in which rivaroxaban
surprisingly had little effect on the RVVT-based activated protein C resistance
assays, despite reports of interference with the APTT-based assay.163
2.6 DOAC CONCENTRATIONS IN HEALTHY
INDIVIDUALS AND IN PATIENT POPULATIONS
During DOAC development, the effects of the drugs were tested in healthy
individuals, which amounted to concentration data. In Table 1, concentration
data by LC-MS/MS most relevant to the currently recommended maximum
dosages of the DOACs are presented. These early studies, as discussed with the
individual DOACS, often used concentrations not in the current summary of
product characteristics for safety assessment, while the concentrations used in
the patient studies were simulated in pharmacokinetic models.108,121 Indeed,
the expected concentrations of DOACs at peak and trough levels are often
derived from these studies.164 The small sample size and mostly male
population in the small series using actual concentration measurements make
it difficult to draw conclusions on the concentrations encountered in patients.
Table 1. DOAC concentrations in pharmacokinetic studies in healthy volunteers
BID, twice daily; SD, standard deviation
Since DOACs have been approved for use in thromboprophylaxis and














level (h)mean SD mean SD
Dabigatran165 17 65-87 9/8 150 mg BID 256 58 79 23 3
Rivaroxaban76 7 20-45 7/0 10 mg BID 158 30 - - 3
Apixaban166 6 24-41 6/0 5 mg BID 129 13 50 10 4
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actual DOAC concentrations in patient populations to ascertain that the
responses seen in the pharmacokinetical models are realised in a real-life
setting. Dabigatran has the most studies published thus far, as this drug has
been on the market the longest. Table 2 lists studies where DOAC
concentrations were assessed in actual patient samples post-authorization.
The patients were recruited at phase IV, with the expection of the Reilly 2014
study conducted in the phase III RE-LY trial for dabigatran.
Most of the studies were performed on patients undergoing orthopaedic
surgery, where the lower DOAC dose was used. It is likely that the drug peak
concentrations encountered in AF and DVT patients might be higher due to
the higher treatment dose. However, even in the patients where the higher
DOAC dose was used with dabigatran peak levels at the 150 mg BID dose
approximately 120-180 ng/mL and trough levels of 70-120 ng/mL reached,
significantly lower than the 256 ng/mL peak and 79 ng/mL trough levels in
healthy volunteers.119,165,167,168 With rivaroxaban, the trough levels were
estimated to be approximately 30 ng/mL in the pharmacokinetic estimations
for the 20 mg OD dose, corresponding to the actual measured concentrations
with that dose.108,168 With the orthopaedic prophylactic dose of 10 mg OD,
trough levels as low as 5 ng/mL were observed.169 With apixaban in a patient
study with 5 mg BID dosing, a significantly higher peak (160 ng/mL) and
trough level (100 ng/mL) were reached than in healthy volunteers (129 ng/mL
peak, 50 ng/mL trough).166,168 A trend of higher concentrations emerges in
studies with mixed indications for DOACs as opposed to use in
thromboprophylaxis in the setting of orthopaedic surgery.
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3 AIMS
DOACs are increasingly used for patient anticoagulant therapy and the need
for laboratory coagulation testing for these drugs will increase. Specific assays
should be widely available, on a 24 hours/7 days per week basis, to support
management at on-call hours. We firstly assessed DOAC effects in in vitro
samples spiked with dabigatran, rivaroxaban or apixaban. Their effects on
screening assays and effects of different reagents used in laboratories were
analysed. We then examined their effects in patient samples on a wide variety
of coagulation parameters.
The specific study aims were to determine:
1) The effects of dabigatran, rivaroxaban and apixaban on coagulation
screening tests INR and APTT in a European laboratory survey conducted in
conjunction with an external quality assessment (EQA) round (I-II).
2) The effects of dabigatran (I, III) and rivaroxaban (I) on the screening
coagulation assays PT, INR and APTT as well as specific coagulation assays
and TG (III) in unselected patient samples.
3) The effects of apixaban and rivaroxaban on basic laboratory variables,




4 MATERIALS AND METHODS
4.1 SPIKED SAMPLES
Lyophilised pooled human plasma samples spiked with dabigatran,
rivaroxaban or apixaban were sent to European laboratories participating in
the EQA rounds of Labquality Ltd for INR, PT and APTT (dabigatran,
rivaroxaban) and anti-Xa (apixaban). The total number of laboratories was 86.
The EQA rounds were conducted in July 2011 (dabigatran), January 2012
(rivaroxaban) and September 2015 (apixaban) and the results were published
in studies I and II. The dabigatran, rivaroxaban and apixaban samples were a
generous gift from Boehringer Ingelheim, Bayer and Pfizer, respectively.
Dabigatran samples were sent to 115 European laboratories (Poland n=49,
Finland n=35, Lithuania n=17, Latvia n=9, Estonia n=3 and Iceland n=2),
rivaroxaban samples to 38 laboratories (Finland n=18, Norway n=9, Ireland
n=5, Denmark n=2, Sweden n=2, Estonia n=1 and Lithuania n=1) and
apixaban samples to 28 laboratories (Finland n=20, Denmark n=1, Estonia
n=1, Greece n=2, Iceland n=1, Ireland n=2, Norway n=1). In the apixaban
round, it was determined that 10 of the laboratories were university centres,
among which 5 were in Finland. The laboratories were instructed to
reconstitute the samples adding 1.0 mL distilled water, to mix thoroughly and
to incubate for 30 minutes at room temperature before analysis.
The lyophilised samples had a final drug concentration of 120 and 300
ng/mL (Aniara) for dabigatran, 60, 146 and 305 ng/mL (Technoclone) for
rivaroxaban and 80 (Diagnostica Stago), 120 (Technoclone), 270 (Stago) and
300 ng/mL (Technoclone) for apixaban. Laboratories were asked to use
screening tests INR, PT and APTT, as well as specific methods for drug-
concentration assessment: TT and calibrated dTT for dabigatran and
calibrated anti-Xa for rivaroxaban and apixaban, respectively. For apixaban,
laboratories were also specifically asked to assay the samples using their
routine anti-Xa assay calibrated for LMWH monitoring as well. The number
of laboratories reporting results was 73 (63.5%), 22 (57.9%) and 21 (75%) for
the dabigatran, rivaroxaban and apixaban rounds, respectively. For
rivaroxaban, in addition to the samples, calibrators with rivaroxaban
concentrations of 0, 14, 60, 100 and 150 ng/mL were sent to the 18
participating Finnish laboratories to help set up a calibration of the local anti-
Xa assay of rivaroxaban, with 8 laboratories (44%) reporting results with
rivaroxaban calibration. For dabigatran, TT was reported by 11 (15%)
laboratories and drug calibrated-dTT was reported by only one (1%) university
laboratory. For apixaban, 15 laboratories (71%) reported LMWH-calibrated
results, but only 7 (33%) reported apixaban-calibrated anti-Xa results.
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A multitude of different reagents and analysers were in use in the
laboratories surveyed; there were 13 different PT/INR reagents, 4 of the
Owren type, 10 different APTT reagents, 3 different TT reagents and 6
different anti-Xa reagents (Table 3). The number of different coagulometers
used for analysis was 24 (Table 4).
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Table 3. Reagents used by the laboratories participating in studies I and II









PT/ INR Nycotest PT Axis-Shield 8 2 2
Owren Owren's PT Medirox 10 7 12
SPA Stago Diagnostica Stago 19 9 5
Thrombotest Axis-Shield 7 2 -
PT/INR Bioksel System PT  Bio-Ksel 2 - -
Quick HemosIL PT Instrumentation Laboratory 1 - -
Innovin Siemens Healthcare Diagnostics 2 2 -
RecombiPlastin 2G  Instrumentation Laboratory 5 - 2
Roche
Thromboplastin
Roche Diagnostics 1 - -
STA Neoplastin
CIPlus
Diagnostica Stago 2 - -
Technoplastin HIS Technoclone 1 - -
Thromborel S Siemens Healthcare Diagnostics 12 - -
TriniCLOT PT HTF Tcoag 1 - -
INR total 71 22 21
APTT Actin FSL Siemens Healthcare Diagnostics 16 8 7
Bioksel System
APTT
Bio-Ksel 2 - -
Dapttin TC Technoclone 1 - -
Grifols APTT Grifols 2 - -
HemosIL APTT SP  Instrumentation Laboratory 17 5 7
HemosIL SynthasIL Instrumentation Laboratory - - 1
Pathromtin SL Siemens Healthcare Diagnostics 9 - -
STA Cephascreen  Diagnostica Stago 4 2 1
STA PTT Automate
TT
Diagnostica Stago 18 7 3
TriniCLOT aPTT HS Tcoag 3 - 1
APTT total 69 22 20
TT Comesa Thrombin
time
Comesa 1 - -
Siemens Thrombin
Reagent
Siemens Healthcare Diagnostics 7 - -
STA Thrombin Diagnostica Stago 3 - -
TT total 11
Anti-Xa Berichrom Heparin Siemens Healthcare Diagnostics - 2 3
Chromogenix
Coamatic Heparin
Instrumentation Laboratory - 4 2
HemosIL Liquid
anti-Xa
Instrumentation Laboratory - - 5
HemosIL Heparin Instrumentation Laboratory - - 2
Rotachrom Liquid
Heparin
Diagnostica Stago - 1 -
STA Liquid Anti-Xa Diagnostica Stago - 1 3
Anti-Xa total 8 15
APTT, activated partial thromboplastin time; Anti-Xa, anti factor Xa activity; INR,
international normalised ratio; PT, prothrombin time; TT, thrombin time
Laboratory monitoring of direct oral anticoagulants
44
Table 4.  Coagulation analysers used by the laboratories participating in studies I and II
4.2  PATIENT SAMPLES
As the results from the first EQA rounds were obtained, it became evident that
comparison of in vitro spiked samples with patient samples would be
beneficial. In study I, 10 citrate-anticoagulated plasma samples from patients
using dabigatran and 10 from patients using rivaroxaban were obtained. They
were unselected samples, from which a DOAC concentration assessment
request was received in the Helsinki University Hospital Laboratory
(HUSLAB). PT, INR, APTT and drug-calibrated dTT for dabigatran and anti-














Bio-Ksel Bioksel 6000 1 - -
Bioksel Chrom 7 1 - -
Instrumentation
Laboratory
ACL Advance, IL 1 - -
ACL 10000 2 1 -
ACL 9000 3 - -
ACL Elite Pro 2 - -
ACL Top 500 7 4 9















STA Compact 3 1 -
Start 4 10 - -
STAR Evolution 6 8 4
Sysmex Sysmex BCS XP 5 1 1
Sysmex CA 1500 12 5 2
Sysmex CA 500 5 - -




Teco Coatron M2 1 - -
Not reported 3 0 1
Total 73 22 21
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Xa for rivaroxaban were performed. The analyser was Sysmex BCS XP® and
the reagents were Nycotest PT® (for INR and PT) and Actin FSL® (for APTT).
The sample collection was according to the hospital routine protocol: blood
was collected into plastic tubes (BD Vacutainer) anticoagulated with sodium
citrate (3.2%; 109 nM), centrifuged at 2500 x g for 15 min followed by plasma
separation within 2 hours. The vacuum extraction phlebotomy is the preferred
sampling method, but in difficult cases, open blood draw was performed. The
ratio of sample to anticoagulant was meticulously controlled and analysis was
not performed from underfilled or overfilled tubes.
To assess the effects of dabigatran on coagulation in patient samples, in
study III, a retrospective analysis was performed on 241 samples from 85
patients, where dabigatran concentration assessment was requested in
HUSLAB. The patient samples were accumulated over a 5-year period (2008-
2013). All consecutive plasma samples were included in the study, but patient
characteristics and treatment indications were not recorded. At that time in
Finland, the indications for dabigatran consisted of thromboprophylaxis after
orthopaedic surgery (dosage 150 mg or 220 mg once daily) and
thromboprophylaxis in the setting of non-valvular AF (dosage 110 mg or 150
mg twice daily). The request of the assay was unlimited; all physicians in the
hospital district could request the assay. It was, however, recommended by the
laboratory that testing should be performed in special circumstances only, i.e.,
major bleeds, thrombosis, hepatic or renal failure or emergency surgery and
to simultaneously assess PT and APTT. The samples were collected and plasma
was separated according to the routine hospital protocol, with aliquots of the
plasma preserved at -80 °C before analysis. In a subset of 49 samples from 35
patients, a large panel of coagulation assays was performed, including the anti-
IIa, ECA, PiCT, RVVT, fibrinogen, D Dimer and TG in CAT®. In a subset of
samples (n=21), the validity of the dTT method was analysed by LC-MS/MS
analysis of dabigatran concentration.
Result interpretation of samples from patients using DOACs is difficult if
the clinical situation of the patient and the time from last drug intake are not
known. To obtain some indication-specific understanding, we conducted
study IV on patients using rivaroxaban or apixaban for thromboprophylaxis
after THA. This study included patients undergoing THA with the direct
posterior technique, where a thromboprophylaxis of 30 days using
rivaroxaban or apixaban was planned. Apixaban patients (n=22) were
recruited from the Kymenlaakso Central Hospital (Kotka, Finland by
orthopaedic surgeon Mikko Manninen) and rivaroxaban patients (n=20) were
recruited from the Helsinki University Peijas Hospital (Vantaa, Finland, by
orthopaedic surgeon Jarkko Leskinen). The doses were 10 mg once daily
(rivaroxaban) and 2.5 mg twice daily (apixaban). Both rivaroxaban and
apixaban were started at postoperative day 1, 24 hours after surgery. With
rivaroxaban, there was a single dose of enoxaparin 40 mg administered on
postoperative day 1, 6 to 10 hours after surgery. This was routine practice in
the orthopaedic ward to secure the anticoagulant effect, in case the patient
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experienced  emesis  and  was  unable  to  ingest  the  drugs.  With  apixaban,  no
thromboprophylaxis on the day of operation was used. The exclusion criteria
consisted of active malignancy, anticoagulant (warfarin, LMWH,
fondaparinux) or antithrombotic (clopidogrel, dipyridamole, prasugrel,
ticagrelol)  medication,  with  ASA being  allowed at  up  to  100 mg once  daily,
bleeding tendency, inflammatory bowel, rheumatic or liver disease affecting
coagulation, phospholipid antibody syndrome or positive lupus anticoagulant,
severe renal insufficiency (estimated GFR < 30 mL/min), pregnancy,
breastfeeding, contraindication to rivaroxaban or apixaban and age under 18
years.
The  blood  samples  in  study  IV  were  collected  at  7  time  points:  1)
preoperatively, 2) on postoperative day 1 before drug intake, and 3) 3 hours
after drug intake, 4) on postoperative day 2 to 8 before and 5) 3 hours after
drug intake and 6) on approximately postoperative day 28 before and 7) 3
hours after drug intake. The rationale for this arrangement was that the drug
effects could be assessed at peak and trough levels at different time points
during recovery and that these can then be compared to the preoperative
baseline. The samples were collected according to the local hospital protocol.
Routine laboratory assays were immediately performed, with a portion of the
citrated plasma stored in aliquots at -40°C until further analysis.
Written informed consent was requested from patients participating in the
study. The study protocols were approved by the Ethics Committee of Oulu
University hospital, mandating a nationwide study.
4.3 LABORATORY ASSAYS
All the coagulation samples were analysed in HUSLAB (Helsinki University
Hospital). The screening assays were performed according to standard
hospital protocol. The specialised assays were handled and processed by a
laboratory technician skilled in coagulation analyses. The different
coagulation assays and their use in the studies is summarised in Table 5.
In the dabigatran study (III), the native TT was used to assess dabigatran
levels below the limit of detection in the dTT assay (40 ng/mL). It was assumed
that the TT changes linearly with increasing dabigatran levels. TT < 60 s was
set to correspond to 0 ng/mL of dabigatran, TT 60-100 s to 10 ng/mL, TT 100-
120 s to 20 ng/mL and TT 120-140 s to 30 ng/mL. These data from the native
TT and the dTT were combined to obtain functional dabigatran concentration
estimates (Dabi-TT) covering the entire concentration range.
In the anti-IIa assay, 25 μL of sample was mixed with 50 μL of substrate
and the reaction was started with 250 μL of thrombin reagent. In the ECA, 25
μL of plasma was mixed with 100 μL prothrombin buffer and further mixed
with 25 μL of ECA substrate, incubated for 1 minute at 37°C, after which the
reaction was started with 50 μL of the ecarin reagent. The specific coagulation
assays ECA and anti-IIa were calibrated with dabigatran concentrations of 0,
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30, 250 and 510 ng/mL to enable measurement of dabigatran concentration.
The  PiCT  was  executed  with  a  two-step  protocol:  50  μl  of  plasma  was
incubated with 50 μL of the activation reagent, after which the mixture was
incubated for 180 s at 37°C, before addition of 50 μl start reagent (calcium
chloride).
In addition to the coagulation assays, in study III mass spectrometry was
used to confirm the validity of the dabigatran assays in a subgroup of 21 plasma
samples. This LC-MS/MS assay was performed by Yuko Rönnquist-Nii from
plasma samples at the Karolinska Institutet, Sweden. Protein precipitation
was done with acetonitrile solution containing the internal standard
dabigatran-d3 (Toronto Research Chemicals), in which three deuterium
molecules were added to the native dabigatran. Dabigatran was detected by
positive electrospray ionization, with selective reaction monitoring to ion
transitions 472 to 289 m/z for dabigatran and 175 to 292 m/z for the internal
standard dabigatran-d3. The assay has a lower limit of detection of 1 ng/mL
for dabigatran, with a linear range of 1.1-412 ng/mL.
In the study of rivaroxaban and apixaban effects in orthopaedic patients
(IV), in addition to the coagulation tests a large panel of basic laboratory assays
was included to understand the extent of inflammation and grade of organ
dysfunctions. These assays included: Blood cell count, CRP, ALT, albumin,
and creatinine and GFR using the MDRD formula. These assays were
performed immediately after sample collection in the routine hospital
laboratory with standard procedures.
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Table 5  Coagulation assays performed in the Helsinki University Hospital Laboratory
(HUSLAB)
Anti-IIa, anti thrombin (IIa) activity; anti-Xa, anti factor Xa activity; APTT, activated
partial thromboplastin time; dTT, diluted thrombin time; ECA, ecarin clotting activity;
F1+2, prothrombin fragment assay; FVIII:C, FVIII clotting assay; INR, international
normalised ratio; PT, prothrombin time; PiCT, prothrombinase induced clotting time;
RVVT, Russel’s viper venom time; LMWH, low molecular weight heparin. *Values
from literature, not locally verified. ** Reference interval changed from    <41 s to
<35 s between studies III and IV
TG was performed on the samples in studies III and IV. All TG tests were
performed by the same researcher (TH) to ensure consistency. The TG test was
performed using the CAT® device (Diagnostica Stago, Thrombinoscope,
Maastricht, The Netherlands). The platelet-poor plasma (PPP) was separated
using the standard laboratory protocol and subsequently frozen (-40 to -
80°C). Before analysis, the sample was rapidly warmed to 37°C and examined.
The reaction temperature significantly affects the output, so the water used for
instrument rinsing and all the samples and reagents (except the small volumes










PT/INR Axis-Shield Nycotest PT 70-130% 6-170% I-IV
APTT Siemens Healthcare
Diagnostics





17-25 s 12-140 s I,III


















































PiCT* Pentapharm Pefakit PiCT 19-31 s 19-250 s III
Anti-Xa Rivaroxaban Aniara Anti-Xa Riva NA 15-1600
ng/mL
I,IV
Anti-Xa Apixaban Aniara Anti-Xa Apix NA 25-2000
ng/mL
II,IV
RVVT** Sekisui Diagnostics DVVTest 10 <41 s/<35 s NA III-IV
F1+2 Siemens Healthcare
Diagnostics
F1+2 NA NA IV
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were done using the Stago PPP reagent® with  5  pM  TF  and  4  μM
phospholipids, without corn trypsin inhibitor addition. Firstly, 2400 μL of
fluorogenic buffer (Stago Fluo-buffer®) was warmed to 37 °C in a water bath.
The analyser was primed (rinsed) with room-temperature water. A 96-well
plate was used for the analysis. The measurement wells were first filled with
20 μL of the reagent or calibrator, with two measurement wells per sample,
containing PPP reagent and one well (III) or two wells (IV) for calibration with
Stago Thrombin Calibrator®. The samples, 80 μL, were then pipetted into the
wells. The pipetting was performed with the reverse pipetting technique to
prevent the introduction of air bubbles into the sample. The plate was then
inserted into the analyser for a 10-minute incubation, to ensure that the
sample temperature was constant at 37°C. The analyser was then rinsed with
37°C distilled water (at least 5 mL) to ensure that the internal temperature of
the analyser reached 37°C. The fluorogenic substrate, 60 μL, was then added
to the 37 °C fluorogenic buffer and the solution was quickly vortexed.
Immediately after preparing the solution, the analyser was filled with the
fluorogenic substrate using the built-in dispensing system. The dispenser was
then reconnected to the analyser to start the automatic measurement. The
device then automatically dispensed the fluorogenic substrate with the
activator into the sample, periodically measuring thrombin formation by
calculating the values by comparing to the fluorogenic calibrator. The
measurement time was 60 minutes. In study III, plasma from individual
healthy volunteers was used as a reference material. Pooled plasma from
healthy volunteers was used in study IV.
4.4 STATISTICAL ANALYSIS
For studies I and II, different reagent groups were compared to one another
using analysis of variance (ANOVA) and pair-wise Student’s t-test. Variations
among the assays were expressed as coefficient of variation (CV). Pearson’s
correlation was used to determine the accuracy of the specific anti-Xa assays.
For studies III and IV, Pearson’s correlation was used to determine the
accuracy of the specific assays in comparison to functional concentration as
determined by dTT for dabigatran and rivaroxaban- and apixaban-calibrated
anti-Xa, respectively. The means for different sample groups were compared
with the pair-wise Student’s t-test (for normal distributions, such as routine
analyses haemoglobin and albumin) and Mann-Whitney’s U test (for non-
normal distributions, such as drug concentration levels and TG).
The p-value significance limit was set at p=0.05, with results below this
value being considered statistically significant.
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5 RESULTS
5.1 DOAC EFFECTS ON COAGULATION ASSAYS IN
SPIKED SAMPLES
5.1.1 PT/INR
The effects of dabigatran and rivaroxaban (study I) and of apixaban (study II)
on coagulation screening tests were examined. The laboratories had 13
different thromboplastin reagents in use (Table 3). The INR was used, as some
laboratories reported the PT in seconds and some as activity percentage, thus
preventing direct comparisons. A total of 71 laboratories reported INR values
for dabigatran. Both dabigatran concentrations (120 ng/mL and 300 ng/mL)
showed that INR increased above the baseline of 1.0, with responses being
stronger in the 300 ng/mL group (Table 6). The different reagents had
different sensitivities. The Owren reagents as a group were less sensitive than
Quick reagents to dabigatran (Figure 3A; p<0.001). The relative change in the
INR between dabigatran concentrations of 120 ng/mL and 300 ng/mL sample
was on average only 1.21 (range 1.11-1.55).
With rivaroxaban (plasma concentrations of 60, 146 and 305 ng/mL), 22
laboratories reported INR values. Five different thromboplastin reagents were
used. The increase in INR was less clear with rivaroxaban than with
dabigatran, with none of the laboratories reaching INR values of 1.9 or above.
The CVs were smaller than with dabigatran (Table 6). The relative change in
INR between the lowest and highest rivaroxaban concentration was on average
1.25 (range 1.14-1.43). There was a significant difference between reagent
sensitivities (Figure 3C; p<0.001), but only two laboratories used a Quick-type
reagent, without significant differences between the Quick and Owren groups.
With apixaban (plasma concentrations of 80, 120, 270 and 300 ng/mL), 21
laboratories reported the INR using 4 different reagents. The INR was inert,
with very little prolongation between the lowest and highest concentrations
(Table 6; Figure 4A). None of the laboratories reached INR of 1.6. The mean
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Figure 3 Study I, dabigatran and rivaroxaban. There were significant differences between
Owren- and Quick-type thromboplastin reagents in the dabigatran group, with
higher sensitivity and variation in the Quick-type reagents with a high variation in
APTT response (3A-B). With rivaroxaban, the responses of INR were modest in all
the reagents, with all values below INR 1.9, with high variation in the APTT
response (3C-D). Median values and range (bars) are shown.
5.1.2 APTT
A total of 72 laboratories reported APTT values with dabigatran. Nine different
reagents were used in the dabigatran round (Table 3). The APTT was sensitive
to the effects of dabigatran, with 70/72 laboratories reporting prolonged APTT
already at the lower concentration of 120 ng/mL. The APTT was significantly
prolonged in this sample on average 23.4 s (range 6.5-41.7 s) above the
reference interval. An even greater prolongation of 53.8 s (range 20.0-89.3 s)
was observed at the higher dabigatran concentration of 300 ng/mL. Again, the
sensitivity of APTT varied widely between laboratories (Figure 3B; p<0.001).
The relative prolongation of APTT was 1.36 (range 1.31-1.62) between the
samples 120 ng/mL and 300 ng/mL, and relative increase above the local




Figure 4 Study II, apixaban. INR had low sensitivity to increasing concentrations of apixaban
(4A). In APTT, the responses varied widely, with modest prolongations of APTT
(4B). Apixaban concentration measurement was sensitive and adequately
reproducible between different laboratories (4C). The anti-Xa with LMWH calibration
exhibited wide reagent-dependent variation, but there was a clear correlation with
anti-Xa result and increasing apixaban concentration. Reagents with added
exogenous antithrombin (asterisk) did not differ from the other reagents (4D)
With rivaroxaban, 22 laboratories reported APTT values using four different
reagents. A dose-dependent prolongation of APTT was observed, but the
increase seemed non-linear. The inter-laboratory variation remained large
(Figure 3D; p<0.001).
With apixaban, 20 laboratories reported the APTT using 6 different
reagents. The prolongation of APTT was modest (mean 7.6 s, range 4-11 s),
with some significant differences between reagents (Figure 4B; p<0.001).
5.1.3 THROMBIN TIME
Although TT is a sensitive method to detect dabigatran, only 11 laboratories
(15%) reported TT results. All laboratories reported TT values above the local
measurement range for both the 120 and 300 ng/mL concentrations. Only one
university laboratory had a dTT available to quantify dabigatran (Hemoclot
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assay), and concentrations of 110 and 320 ng/mL were obtained for the 120
and 300 ng/mL samples, respectively.
5.1.4 ANTI-XA
Anti-Xa assay is sensitive and can quantify rivaroxaban and apixaban when
calibrated for drug level. In the rivaroxaban round, only calibrated anti-Xa
results were requested. Eight laboratories provided results (36%). Two
laboratories reported accurate concentrations for all the samples, whereas six
laboratories underestimated the highest sample concentration. This was
probably due to the calibration, since the highest calibrator concentration sent
to the laboratories was 150 ng/mL. With apixaban, both LMWH-calibrated
and drug specific anti-Xa assays were requested. 15 laboratories (71%)
reported LMWH-calibrated results. There was a dose-dependent increase in
the LMWH-calibrated anti-Xa, but the results varied widely between
laboratories, with CVs of 21-19% within reagent groups with overall CVs of 20-
49% (Table 6; Figure 4C-D). The overall Pearson’s correlation was moderate
(R2=0.69). Seven laboratories (33%) reported apixaban concentration with
calibrated anti-Xa assays with accurate results; the correlation with the actual
concentrations was excellent (R2=0.93). With either rivaroxaban or apixaban,
exogenous antithrombin addition in the anti-Xa reagent had no effect on the
anti-Xa result (p>0.05).
5.2 DABIGATRAN EFFECTS ON COAGULATION IN
UNSELECTED PATIENT SAMPLES
In  study  I,  the  effects  of  dabigatran  on  coagulation  were  assessed  in  10
unselected clinical patient samples. The mean measured dabigatran
concentration was 119 ng/mL (range 100-136 ng/mL). The mean INR was 1.08
(range 0.96-1.17), which was lower than the INR for the spiked sample of 120
ng/mL with the same reagent, Nycotest PT, 1.16 (p<0.01). The APTT showed
significant differences in the patient samples and the spiked sample, with a
mean APTT of 39.8 s (range 33-43 s) in the patient samples, while with the
same Actin FSL reagents, APTT was 54 s (p<0.001) in the spiked sample. In
one patient sample, the APTT was within the local reference interval.
In study III, the TT and dTT results were expressed as functional
dabigatran concentration, Dabi-TT, to cover the full dabigatran concentration
range. The mean Dabi-TT was 71 ng/mL in the 241 patient samples (Table 7).
The undiluted TT was sensitive and at dabigatran levels below 40 ng/mL,
values within the measurement range were obtained. 153/241 (63%) samples
had TT < 140 s (Dabi-TT < 40 ng/mL). There was one outlier, with a TT of 46
s with a Dabi-TT of 160 ng/mL. APTT was normal (29 s).
Results
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Table 7. Study III. Original results in 241 dabigatran patient samples.
APTT, activated partial thromboplastin time; Dabi-TT, diluted thrombin time
calibrated for dabigatran; SD, standard deviation PT, prothrombin time; TT,
thrombin time
The APTT prolongation correlated with Dabi-TT, but the correlation was
curvilinear (linear R2 = 0.68, quadratic R2 = 0.71; Figure 5A-B). One outlier
sample, with APTT above 180 s and Dabi-TT of 46 ng/mL, was excluded from
the analysis. Although APTT generally prolonged with increasing Dabi-TT, in
18/70 (26%) of samples with Dabi-TT values 40 ng/mL or above and 137/241
(56%) of all samples, the APTT was within the reference interval of 23-33 s.
Even at Dabi-TT of 160 ng/mL, one sample had normal APTT (29 s). The PT
results correlated poorly with Dabi-TT (R2 = 0.13). The PT was abnormal (>
24 s) in only 48/241 (20 %) samples. In samples with Dabi-TT of 40 ng/mL or
above, the PT was abnormal in only 26/99 (26 %).
In the 49 patient samples, a full panel of coagulation assays was performed.
Dabi-TT, APTT and PT gave similar results as those performed on all patient
samples (Table 8). The anti-IIa and ECA correlated well with Dabi-TT
(R2=0.90 and 0.89, respectively, Figure 6A-B). The anti-IIa and ECA results
were almost identical to one another (R2 = 0.99, bias = 3.6 %). The PiCT also
correlated moderately with Dabi-TT (R2 = 0.73; Figure 6C). The PiCT values
were prolonged in 33/49 (67%) samples. With Dabi-TT above 40 ng/mL, the
PiCT was often prolonged (in 98% of the samples). The RVVT also correlated
somewhat with Dabi-TT (R2 = 0.49; Figure 6D); the RVVT was normal (< 41
s) in 9/49 (18%) samples, all of which had low Dabi-TT (< 40 ng/mL). The
RVVT was always prolonged when Dabi-TT exceeded 40 ng/mL. The
correlation between RVVT and PiCT results was only modest (R2 = 0.59).
Dabi-TT (ng/mL) TT (s) APTT (s) PT (%)
Mean 71 92 35 94
Median 10 94 33 95
Range 0-1000 15-141 20-180 23-156
SD 118 47 13 27
Normal range NA 17-25 23-33 70-130
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Figure 5 Study III. APTT exhibited a curvilinear relationship with increasing
dabigatran levels (5A; R2 = 0.71). Despite the correlation, the APTT was
often within the normal range at dabigatran levels over 40 ng/mL. The
highest dabigatran concentration in which the APTT was normal was 160
ng/mL (5B)
Figure 6 Study III. Excellent correlation between ECA and anti-IIa calibrated with dabigatran
was seen with dTT dabigatran concentrations (R2=0.90 and 0.89, respectively; 6A-
B). The correlations with PiCT and RVVT to dabigatran concentrations were more
modest (R2=0.73 and 0.49, respectively; 6C-D).
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The Dabi-TT validity was assessed using LC-MS/MS in a subset of 21 samples.
The mean dabigatran level was 73 ng/mL (median 78, range 2-150 ng/mL).
The correlation between Dabi-TT values was good, with Dabi-TT values being
on average 10 ng/mL lower (R2 = 0.81, bias 13.7 %). The correlation was even
better with Anti-IIa and ECA assays, but the bias was larger (R2 = 0.96 and
0.90; bias 18.4 % and 14.5 %, respectively, Figure 7A).
In TG, the lag time was prolonged with increasing Dabi-TT (R2 = 0.51,
Figure 7B). The effect of dabigatran was clear in lag time, with values below 40
ng/mL leading to shorter lag times than with Dabi-TT above 40 ng/mL
(p<0.001). The time to peak had a similar profile. Surprisingly, however, the
ETP and Peak did not behave as expected. In contrast to the expected decrease
in values, ETP and Peak increased with increasing Dabi-TT levels from 40
ng/mL to 225 ng/mL (Figure 7C-D; p<0.001). There was a single sample with
Dabi-TT of 335 ng/mL, where ETP and Peak values were again lower than in
the previous samples with elevated Dabi-TT levels. In addition to these 49
samples, there were 23 samples where valid TG curves were not obtained:
there was a trace of TG curve, but the alpha-2-macroglobulin calibration curve
failed and the samples could not be included in the analysis. These samples
had significantly higher Dabi-TT values (mean 259 ng/mL) than the included
Dabi-TT values (42 ng/mL, p<0.001).
Fibrinogen and D dimer levels were also assessed in the 49 samples, with
no correlation to Dabi-TT. Both the D dimer and fibrinogen levels were fairly
high (Table 8). The two different fibrinogen reagents correlated with one
another excellently at all Dabi-TT levels (R2=0.98; p < 0.001). A correlation
between fibrinogen levels and TG parameters ETP and Peak was absent





































































































































































































































































































































































































































































































































































Figure 7 Study III. Functional dabigatran concentration method correlated with mass
spectrometry (R2 = 0.81; 7A). As expected, increasing dabigatran concentrations
prolonged lag time in TG (R2 = 0.51; 7B). Surprisingly, the ETP and Peak values
increased with increasing dabigatran concentrations, at dabigatran levels above 40
and 120 ng/mL the average values in ETP and Peak were higher than below those
concentrations (p<0.001; 7C-D).
5.3 RIVAROXABAN AND APIXABAN EFFECTS ON
COAGULATION IN PATIENTS
In study I, 10 unselected rivaroxaban samples were assessed with a mean
rivaroxaban concentration of 63 ng/mL (range 32-128 ng/mL). Using the
same reagents, neither the INR nor the APTT results differed from the spiked
sample of 60 ng/mL, with modest prolongation of APTT and minimal effect
on the INR.
In study IV, the rivaroxaban and apixaban patients undergoing orthopaedic
surgery had their basic characteristics recorded. The mean age for rivaroxaban
patients was 67 years (range 44-82). 15/20 patients (75 %) were women and
mean body mass index (BMI) was 28.8 kg/m2 (range 21.0-39.0). The mean
age for apixaban patients was 68 years (range 52-82). 12/22 (55%) patients
were women and mean BMI was 27.2 kg/m2 (range 20.0-40.0).
Haemoglobin and albumin decreased in all patients at day 2-8, with the
lowest mean values being 109 g/L (range 78-132 g/L) and 29 g/L (range 24-37
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g/L), which are well below the lower reference limit. Leukocytes and CRP
increased initially in all, reaching a plateau at day 2-8, and decreasing towards
normal at day 28. Platelet count remained in the normal range, without any
significant changes during the study, as did ALT and creatinine. (Table 9)
In the drug-calibrated anti-Xa activity, both rivaroxaban and apixaban
levels varied significantly in individual patients. The mean peak
concentrations after first doses were 111 ng/mL (range 7-267 ng/mL) for
rivaroxaban and 19 ng/mL (range 0-73 ng/mL) for apixaban. The mean steady
state highest peak level measured was for rivaroxaban, on day 28 at 184 ng/mL
(range 81-355 ng/mL) and for apixaban on day 2-8 at 135 ng/mL (range 17-
301 ng/mL). The lowest trough levels on day 28 were 16 ng/mL (range 0-48
ng/mL, rivaroxaban) and 46 ng/mL (range 0-103 ng/mL, apixaban) (Figure
8).  Three  patients  with  rivaroxaban  and  one  patient  with  apixaban  had
undetectable lowest trough level. Drug concentrations did not correlate with
BMI or GFR.
Figure 8 Study IV. Rivaroxaban and apixaban presented significant differences in their peak
and trough levels. Mean values and 95% confidence intervals (bars) are shown.
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The PT correlated slightly with rivaroxaban concentration (R2=0.18,
p<0.001), but not with apixaban. The APTT correlated somewhat with
rivaroxaban (R2=0.44, p<0.001), but the correlation with apixaban was poor
(R2=0.07, p=0.007). Both the PT and the APTT remained within the reference
intervals for both anticoagulants at all time points. The PT and APTT data have
been pooled in Table 9.
There was a distinct effect with rivaroxaban and apixaban in TG. While
both drugs diminished the ETP and Peak, the response was more vigorous
with rivaroxaban than with apixaban. Both drugs prolonged the lag time even
at low concentrations (Figure 9A). The trough level change in ETP was marked
with apixaban. ETP and Peak were close to the baseline levels at lowest trough
on day 28 with rivaroxaban (Figure 9B-C). However, with apixaban, there was
a significant inter-individual variation in the TG responses (Figure 10). In one
68-year old patient on postoperative day 2-8, while there was an increase in
apixaban levels from 50 to 115 ng/mL (delta 65 ng/mL, 130%), ETP actually
increased from 1251 to 2036 nM/min (delta 786 nM/min, 62%). The Peak
value also increased (delta 210 nM, 106%) and lag time decreased (delta 30 s,
8%; Figure 10A, square). In comparison there was another patient of similar
age and apixaban concentration, at the same time point, a 73 year-old patient
with apixaban delta of 59 ng/mL, from 86 to 156 ng/mL (67%). In his sample
there was an expected decrease in ETP from 1543 to 1140 nM/min (delta 401
nM/min, 26%, Figure 10A, triangle), with the Peak also decreasing by 95 nM
(24%) and lag time prolonging by 80 s (27%). With rivaroxaban there were no
patients with such a paradoxical change in TG parameters (Figure 10B).
In the special coagulation assays, there was a clear prolongation in RVVT
at rivaroxaban peak levels, but not with apixaban (Figure 9D). There was a
peak in fibrinogen and FVIII:C activity on day 2-8, consistent with the
inflammatory state (Figure 11A-B). In contrast, D dimer levels were high
throughout the study period, being borderline elevated even at baseline. D
dimer levels reached a peak at day 1, nadir at day 2-8, and yet another peak at
day 28 (Figure 11C). There was no discernible change in the prothrombin
fragment F1+2 levels (Figure 11D). The antithrombin activity decreased
slightly at day 2-8 but did not decline below the lower reference limit at any
time point (Table 9).
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Table 9. Study IV. Basic laboratory tests during the study period, with mean values, 95%
confidence intervals and local reference ranges. Haemoglobin and albumin were
significantly decreased during the study, reaching a nadir at day 2-8. The
inflammatory markers CRP and leukocytes increased with no discernible changes
in platelets, ALT or creatinine. The results were pooled as the coagulation tests PT,
APTT and antithrombin all remained within the reference intervals throughout the
study, with minor differences between rivaroxaban and apixaban.
ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; CI,
confidence interval; CRP, C reactive protein; Hgb, haemoglobin; PT, prothrombin
time; Preop, preoperative; Day 1, postoperative day 1; Day 2-8, postoperative day
2-8; Day 28, postoperative day 28; Ref range, reference range. * Post drug intake
values
Preop Day 1 Day 2-8 Day 28 Ref range














































































































Figure 9 Study IV. Both apixaban and rivaroxaban prolonged TG lag time and diminished
ETP and Peak values. Rivaroxaban exhibited a stronger response (9A-C). With the
RVVT, there was little change with apixaban, whereas with rivaroxaban, the RVVT
was invariably prolonged at peak levels (9D). Mean values and 95% confidence
intervals (bars) are shown. The upper limit of normal range is shown in RVVT.
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Figure 10 Individual patient responses to rivaroxaban and apixaban in TG ETP varied greatly
at day 2-8. Changes in drug concentration and ETP are shown. The ETP is
expected to have a negative change with increasing DOAC levels. With apixaban,
however, in two different patients with a similar concentration change in the drug
levels (before and after drug intake), the ETP was diminished in one patient (10A,




Figure 11 There was a clear peak with fibrinogen and FVIII:C in day 2-8 (values before drug
intake), consistent with the proinflammatory status of the patients, with little
differences between the anticoagulants (11A-B). Surprisingly, the D dimer levels
were above the reference interval almost throughout the study period, with another
increase in the levels at day 28 after an initial decrease at days 2-8 (11C). The
prothrombin fragment levels F1+2 remained stable throughout the study (11D).
Mean values, 95% confidence intervals (bars), reference intervals, and for FVIII a
190 IU/dL reference point are shown.
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6 DISCUSSION
6.1 EFFECTS OF DOACs IN SPIKED SAMPLES
In general, no routine coagulation monitoring of DOACs is necessary.
However, in several clinical situations (such as emergency surgery, severe
thrombosis  or  bleeding),  it  is  crucial  to  assess  the  effects  of  these  drugs  on
coagulation, often in emergency care setting. The effects of DOACs onto
laboratory coagulation assays have been extensively studied in vitro in spiked
samples. A general consensus exists that laboratories should offer coagulation
testing in this setting.5,176,177 A total of 13 different PT reagents and 10 different
APTT reagents were used in the study laboratories (studies I and II), in various
combinations and in 24 different types of analysers (Tables 3-4). The
laboratories should be aware that no single study or previous survey can cover
the vast spectrum of different reagents and analysers used. Furthermore,
DOAC responses to different coagulation assays reported in the literature are
unlikely to be reproduced in the clinical laboratory setting, unless the same
analyser and reagents are used. Even under these conditions, local verification
of results is recommended.
In  our  studies  I  and  II,  the  INR  was  assessed  in  the  spiked  samples  for
DOAC effects as laboratories reported the PT results diversely; some reported
values in seconds and some as activity percentage compared to normal values.
In these surveys, the INR was insensitive to the effects of dabigatran,
rivaroxaban and apixaban, in agreement with previous studies.5,9,121,178 The
novel information obtained in our EQA surveys was that the Owren-type
thromboplastin reagents, which most of the laboratories used, were
significantly less sensitive to DOAC effects than the Quick assay. This was
possibly due to the higher dilution factor of plasma (1:20) (Figure 3A, 3C, 4A).
It is also noteworthy that the reagents used vary and recommendations on
monitoring should not be based on a single reagent. It has previously been
shown that Neoplastin CI Plus® reagent (Diagnostica Stago) is more sensitive
to the effects of rivaroxaban than other PT reagents, but none of the
laboratories participating in the rivaroxaban survey used that reagent.7,117 It
should be noted that INR was selected as a comparator assay between
laboratories for practical reasons. Laboratories were able to report INR
consistently as all laboratories offering coagulation services have the method
available. Indeed, the PT would be the preferred assay, as the INR standards
are generated using patient samples with warfarin anticoagulation. The
differing ISI of the reagents can magnify the differences between reagents,
even though the ISI values in the surveys conducted were close to 1.0 (with a
range of 0.9-1.3 according to the manufacturers).114,179 The PT assays might be
insensitive to DOACs, due to the dilution of 1:3 (Quick method) or 1:20 (Owren
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method) of plasma. In contrast, in POC assays with no dilution, there was a
response in PT to various DOACs.157,160
Modifications to PT or INR have been suggested to monitor the effects of
DOACs. It was suggested that the ISI used for INR could be calibrated using
rivaroxaban instead of a VKA, with results obtained using the Quick reagents
more sensitive to the effects of rivaroxaban.179 Recently, a single-test approach
was assessed in association with dabigatran, rivaroxaban and apixaban, where
a diluted PT and a modified PT with plasma deficient only in FII and FX, the
so-called Fiix-PT test, were used with encouraging results.180 However, a
completely novel method has the disadvantage of difficulties in widespread
laboratory implementation, especially prior to the availability of commercial
reagents.
In our in vitro survey, the APTT was almost uniformly prolonged when
dabigatran was present. However, the prolongation varied by two-fold. The
Stago PTT® emerged as the most sensitive reagent among those surveyed;
Actin FSL® was the least sensitive. Both supporting and contradictory findings
to this have been previously reported, possibly due to the high degree of
variation among assay performance.6,161 The CVs were almost 20% in our
study. The APTT has been previously recommended as an indicator test for the
presence of dabigatran.10 While the in vitro data supports this, subsequent
patient sample studies (among them study III) have shown that APTT can
often be normal with significant amounts of dabigatran in the plasma.
Rivaroxaban and apixaban had very modest prolongations in APTT with
increasing concentration. These findings are consistent with previous
studies.7,8,181 From previous experience with heparins, it can be deduced that
APTT reacts more strongly to thrombin inhibitors than FXa inhibitors. This is
because unfractionated heparins, which prolong APTT inhibit both thrombin
and FXa, while low molecular weight heparins, only inhibiting FXa, do not.182
Only a minority of the laboratories were able to offer DOAC-specific
coagulation assays at the time studied, thus exemplifying the diverse
conditions on coagulation tests. The TT for dabigatran and drug-calibrated
anti-Xa for rivaroxaban and apixaban were available in 15% (dabigatran
round), 36% (rivaroxaban round) and 33% (apixaban round) of the
participating laboratories. In the apixaban round, the status of the laboratory
(university centre or regional laboratory) was determined. Although there
were 10 university hospitals, only 7 had apixaban concentration assays
available. In another survey, the potential of LMWH-calibrated anti-Xa assays
showed a wide variation in reported responses between laboratories, making
the method suboptimal.183 Similar results have been observed elsewhere, with
approximately a third of the laboratories offering specific assays.184 This
highlights the fact that many laboratories only provide the basic coagulation
assays. Thus, it is crucial for all laboratories providing coagulation testing to
understand the effects of these DOACs on their particular assay-reagent-
analyser combinations.
Laboratory monitoring of direct oral anticoagulants
68
Our surveys showed that when laboratories were able to provide specific
assays for DOAC measurements (namely drug-calibrated TT for dabigatran
and drug-calibrated anti-Xa for the FXaIs), the obtained drug concentrations
were reasonably close to the spiked concentrations. It seems that the
methodology to accurately assess drug concentrations is commercially
available and can be maintained with relatively low cost. The problem with
laboratories is two-fold: on one hand, the paucity of the requests for these
specific assays in smaller laboratories might make it difficult to justify the
added cost. On the other hand, even with the specific assays available, the
knowledge must be distributed in the field so that clinicians will request the
appropriate assay for the patient.
6.2 DABIGATRAN EFFECTS ON COAGULATION IN
UNSELECTED PATIENT SAMPLES
With the in vitro data obtained from the EQA rounds and discrepancies with
the APTT sensitivity observed in a subgroup of 10 unselected patient samples,
a larger study with 241 patient samples was performed to understand
dabigatran effects on coagulation in patients. The unselected patient material
provided a real-life snapshot of the samples laboratories are likely to analyse.
The median levels of dabigatran were very low (10 ng/mL), suggesting that in
many patients the concentration assessment was used to exclude dabigatran
influence. Indeed, in almost all of the samples the dabigatran levels were below
300 ng/mL. While no routine monitoring is advocated, in patients with
extremes of body weight, impaired renal function and impending surgery,
concentration measurements are a valuable addition to the bleeding risk
assessment, as dabigatran levels correlate with both bleeding and thrombotic
complications.170 In this study, it was clearly shown that both PT and APTT are
unreliable for dabigatran analysis, with normal results observed in samples
with significant concentrations of dabigatran. The findings are reagent-
dependent and apply to the reagents used in the study (Actin FSL and Nycotest
PT), with some assays being significantly more sensitive.118 The thrombin-
specific assays (dTT, ECA and Anti-IIa) measured dabigatran with high
precision, as confirmed by LC-MS/MS. LC-MS/MS remains the gold standard,
as it was observed that the correlation between dTT and LC-MS/MS was
suboptimal at dabigatran concentrations below 50 ng/mL, consistent with
previous studies.141,143 However, the clinical relevance of these low drug levels
might be limited.
The RVVT and PiCT also exhibited linear responses, but with higher
variation. With dabigatran concentrations above 40 ng/mL, the RVVT and
PiCT were almost invariably prolonged (Figure 6 C-D). These characteristics
suggest these assays might be suitable for qualitative assessment of
dabigatran. With the RVVT in routine use in many laboratories as part of the
lupus anticoagulant screen, it could be easily adopted for this purpose. On the
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other hand, presence of dabigatran should be excluded to ensure accurate
assessment when detecting lupus anticoagulant in a patient.132
In TG, there were expected and surprising findings on dabigatran. As
expected, lag time was prolonged with increasing dabigatran concentrations,
as previously described.156,169 A new and contradictory finding to many
previous studies was that the ETP and Peak values were high when compared
to normal samples and were further increased with increasing dabigatran
concentrations.155,156,169,185,186 However, the same phenomenon has been
observed in two studies with patients undergoing orthopaedic surgery.172,187 It
should be noted that in the TG assays we performed, only a single
centrifugation step was performed as all the patient samples were collected as
part of a routine hospital protocol. However, this does not affect ETP and Peak
values when the high TF concentration of 5 pM is used.188 Furthermore, the
reference samples from healthy volunteers were also centrifuged only once to
enable comparison. The clinical situation of the patients was unknown, so its
effect on the TG results cannot be directly assessed. It is likely that patients
undergoing thrombosis or surgery were included; these patients probably
exhibit enhanced TG. However, this still does not explain the increase in TG
with increasing dabigatran concentration. It is quite possible that dabigatran
exhibits different effects on patients with high risk for thrombosis, as
thrombin inhibitors inhibit the thrombomodulin-mediated activation of
protein C.189,190 It has also been suggested that dabigatran impacts the alpha-
2-macroglobulin-thrombin complex used for the calibration of the assay. This
leads to erroneously high results, with the effect being notable at drug levels of
under 200 nM (94 ng/mL).147,172,187,191 The assay also often failed in the
calibration, especially at higher dabigatran concentrations, pointing towards
an issue in the assay. Due to these confounding factors, the relevance of these
findings is speculative and it remains to be assessed in future studies. The
effect of calibration alone is an unlikely culprit, as a similar paradoxical
increase has also been observed with prothrombin fragments F1+2.192
Recently, a modified TG test using an alternative calibration method has been
assessed with dabigatran. The modified method did not show the increase in
TG parameters at lower concentrations of dabigatran.193
Since the samples were from unselected patients, no clinical data or timing
after drug intake was available. It can be assumed, however, that since the
measurement of drug concentration was requested, the patients had a clinical
need as routine monitoring is not performed. Both the fibrinogen levels and
the  D  dimer  levels  were  high  in  most  of  the  patients,  but  there  was  no
correlation between D dimer levels and dabigatran correlations. As dabigatran
is known to affect the fibrinogen methods differently at dabigatran levels over
200 ng/mL, two methods with different sensitivities were assessed.161
However, no conclusions could be made since so few samples (3/49 samples)
had dabigatran levels over 200 ng/mL. The high fibrinogen and D dimer are
relevant, as it underscores the need for clinicians to look at the overall status
of the patient instead of relying on a single assay. Even the concentration
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assessment does not reveal the full status of the patient undergoing
anticoagulation with a DOAC.
6.3 RIVAROXABAN AND APIXABAN EFFECTS ON
COAGULATION IN ORTHOPAEDIC PATIENTS
In study IV on patients undergoing orthopaedic surgery using apixaban
(n=22) or rivaroxaban (n=20), there were the advantages of recorded drug
intake times and known patient clinical situations. It was expected (but
nevertheless important) that the patients exhibited large inter-individual
variation in both rivaroxaban and apixaban drug concentrations. Consistent
with their dosing, the once-daily dosed rivaroxaban exhibited higher peak
levels and lower through levels than the twice-daily dosed apixaban. This was
observed previously in patients undergoing orthopaedic surgery, and the drug
levels were comparable to previous studies.169,172-174 AF  patients  also  have  a
similar wide variance of drug levels, as previously observed with both
rivaroxaban and apixaban.194,195 Notably, there were patients with both
rivaroxaban and apixaban where the trough level drug concentration was
immeasurable. However, this was observed in only one patient using
apixaban. Since the peak drug levels in these same patients were detectable, it
seems likely that the effect was due to inadequate dosing rather than non-
compliance.
In TG, both apixaban and rivaroxaban had a clear effect of increasing lag
time and diminishing ETP, using the 5 pM TF with single plasma
centrifugation. There was no such paradoxical change in the variables as
observed with dabigatran. There were, however, differences between the
DOACs. Rivaroxaban inhibited TG vigorously already after the first dose on
postoperative day 1. At this time point there was little increase in apixaban
concentration with small inhibition in TG, consistent with the concentration
difference between the DOACs (Figure 9A-C). However, there is a confounder
with enoxaparin. Enoxaparin was used with rivaroxaban patients before the
administration of rivaroxaban, which impacted both the FXa-based
rivaroxaban concentration assay and the TG assay. This unfortunately makes
the comparison of the initial effects of DOACs difficult to interpret. However,
the differences between the DOACs remained consistent throughout the study
period. With apixaban at steady state on day 2-8, there were two patients with
opposite changes in TG. One exhibited an increase in the ETP and Peak, while
another exhibited a decrease at similar apixaban peak levels of 115 and 156
ng/mL, respectively (Figure 10). The effects of surgery are likely to contribute
to and magnify the individual differences shown in the TG assay. At day 2-8,
the proinflammatory markers CRP, leukocytes and FVIII:C also peaked,
suggesting the inflammatory procoagulant state might be exceeding the
anticoagulant effect of apixaban in this patient. With rivaroxaban, there was a
clear decrease in ETP and Peak at drug peak concentration levels, more
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markedly than with apixaban. However, at trough levels the ETP and Peak
were close to the preoperative, normal levels. This is consistent with the low
rivaroxaban levels (under 50 ng/mL) in all the patients at trough
concentrations. However, lag time was invariably prolonged even at
rivaroxaban trough levels. The lag time corresponds to the initiation phase of
coagulation, where very little thrombin is formed. Thus, it might be sufficient
for even a small amount of the DOAC to affect this parameter, while the effect
on ETP and Peak is smaller. The differences between the DOACs observed in
patient samples are interesting, as in contrast, a previous study with spiked
samples demonstrated that apixaban and rivaroxaban inhibited TG to a
similar degree.156,196
The RVVT showed clear responses to rivaroxaban at peak levels. With
apixaban, the assay was inert even at peak levels. There was no response in
either  of  the  DOACs  at  trough.  It  seems  that  the  RVVT  might  be  used  as  a
qualitative test for rivaroxaban effects, but low levels of the drug might go
undetected. The use of RVVT to assess FXa-inhibitors has been studied.
Surprisingly, in our study apixaban had little effect, whereas rivaroxaban had
a clear effect on the RVVT.104,132,135,162 Differing drug concentrations at peak
levels might explain this result.
With the stress of major surgery, an inflammatory response is expected.
Thus, the increase in the proinflammatory markers CRP, leukocytes, FVIII:C
and fibrinogen was expected and consistent with previous studies.197,198 As
previously reported, a nadir in haemoglobin and albumin was also observed,
probably due to the inflammatory response and blood loss during
surgery.198,199 Simple dilution is unlikely, as leukocyte levels increased while
haemoglobin and albumin levels decreased. Although expected, this finding is
also relevant for the coagulation status of the patients. Haemoglobin is crucial
in primary haemostasis and also provides a procoagulant membrane with
microparticles and promotes TG.200 Both drugs also bind to albumin (95% for
rivaroxaban and 87% for apixaban).113 It has been shown with both
rivaroxaban and warfarin that hypoalbuminemia is an independent risk factor
for intracranial haemorrhage, with the risk highest at albumin levels below 30
g/L.201 This is relevant, as in study IV mean albumin in women was 29 and 28
g/l at days 1 and 2-8, respectively. With the normalization of inflammatory
parameters at day 28, haemoglobin and albumin returned to near normal
levels (Table 9).
The coagulation screening tests PT and APTT reacted minimally to
apixaban and rivaroxaban, remaining within the reference interval in most
cases (Table 9). This underscores the poor performance of these assays in the
assessment of DOAC effects, suggesting that these assays should not be used
in that setting. Surprisingly, contrary to the behaviour of inflammatory
markers, D dimer levels were elevated at all time points in some individuals
and remained elevated at the end of the study period on day 28 in most
patients. There was a nadir in D dimer level at day 2-8 before increasing again
at day 28. It has been previously shown that D dimer levels exhibit a sinusoidal
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pattern after THA, with levels increasing again in postoperative days 2-3.202 A
similar finding has been previously reported in patients undergoing THA with
fondaparinux thromboprophylaxis. Accordingly, D dimer remained elevated
at 4 weeks postoperation.197 It is possible that the patients are still in a
prothrombotic state at 4 weeks, as fibrin formation and degradation are still
ongoing.203 Fibrin  has  a  major  impact  on  the  healing  process,  and  fibrin  in
dynamic interaction with FXIII also affects measured TG.151,204,205
6.4 STRENGTHS AND LIMITATIONS OF THE STUDY
When considering the effects of DOACs on individual patients, the strengths
in this study are most numerous in study IV, where rivaroxaban and apixaban
samples were taken at predetermined time intervals in patients in whom the
clinical situation was known. This information is important when translating
the results in the clinical context. The differences in TG with apixaban patients
at certain time points in convalescence highlight the importance of the overall
coagulation status of the patients. When assessing patient coagulation status,
DOAC concentration assessment alone is not sufficient. Data from patient
samples is substantially different from the in vitro, spiked sample data
obtained from studies I and II. The spiked sample studies showed that Owren
PT was insensitive to all the DOACs, a finding confirmed in the patient sample
studies III and IV.  However, in APTT there was a significant discrepancy
between the spiked sample data, where APTT was clearly prolonged by
dabigatran and the patient sample data, where it was barely prolonged. The
different behaviour of the anticoagulants in TG (i.e. the paradoxical increase
of TG with dabigatran and differences in rivaroxaban and apixaban responses)
was evident in our patient sample data, in contrast with the previously
published spiked sample data. Thus, the findings obtained in in vitro studies
should be verified using patient samples, as significant differences in
responses might occur.
A major strength of this study is the wide-ranging view of the laboratory
aspects of DOAC monitoring. In studies I and II, a major inter-laboratory
difference between reagents, analyser and available techniques was observed,
even though the assays surveyed were relatively basic. Information on the local
availability of specific assays is crucial. Even though the coagulation screening
assays  should  not  be  used  for  DOAC  effect  monitoring,  the  absence  of
appropriate methods in these laboratories has the direct consequence of
inexperience in these assays in the clinical settings that these laboratories
serve. On the other hand, in studies III and IV, we studied patient samples
where DOAC concentrations were primarily unknown. This will increase the
understanding of these drugs in actual patient settings. Firstly, the range of
drug concentrations observed, secondly, the characteristics of other
coagulation and general laboratory parameters with DOACs on board, and
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thirdly, the effects of increasing DOAC concentrations in various coagulation
assays.
Study III interacts between the laboratory surveys assessing in vitro data
and the well-characterised patients in study IV by using unselected patient
samples. The limitation in this approach was that it was impossible to delve
further into the paradoxical TG ETP and Peak increase to assess whether a
clinical thrombogenic factor exists in these patients. The use of unselected
samples can also be considered a strength, as this study represented the
sample material accumulated in a central coagulation laboratory over several
years, giving perspective on the actual drug concentration levels commonly
encountered in laboratories. The fact that the majority of the drug
concentration levels were low (median 10 ng/mL) indicates that laboratories
need to consider methods that are sensitive to therapeutic and subtherapeutic
levels and not rely solely on methods that are only sensitive to
overanticoagulation.
One major limitation of studies III and IV is the use of the TG assay with
single centrifugation of plasma instead of double centrifugation. At high TF
levels, ETP and Peak are not expected to change, but there is a possibility of
different sensitivities to drug inhibition possibly due to the effects of remnant
platelets.188 This means that the TG results obtained in our studies cannot be
directly compared to others, where a double-centrifugation protocol was used.
Another limitation in these studies is the use of the high TF concentration,
which means that the role of the intrinsic activation of coagulation could not
be studied.206 This is especially relevant in study IV, as contact activation is
involved in the healing process after orthopaedic surgery. Also in study IV, the
early use of enoxaparin limits the interpretation of the comparative anti-Xa
inhibition of rivaroxaban and apixaban after the first drug dose.
6.5 FUTURE CONSIDERATIONS
In 2017, the use of DOACs seems to be on the increase. In a recent study, as
DOAC use is increasing, warfarin was used in only about half of the patients
undergoing a clinic visit for AF and in two thirds of patients with DVT.207
Rivaroxaban is the DOAC that is most widely used at the moment, followed by
apixaban and dabigatran.207 In some observational studies, these new agents
were considered to have superior efficacy to warfarin in the setting of AF, with
a similar bleeding risk.103,208-211 The use of these new drugs is also increasing
in VTE.212 The development of antibodies and neutralising agents for DOACs
as an antidote in emergencies will further facilitate the use of these drugs.
Idarucizumab, a monoclonal antibody against dabigatran, is already on the
market. The factor Xa inhibitor antidote andexanet alfa is showing promise in
clinical trials.213-217
The increasing use of these drugs is a challenge to both clinicians and
laboratory specialists alike, as specific coagulation assays will be increasingly
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needed, requested and interpreted.104,218,219 It  should  be  noted  that  even
though PT and APTT are not used for DOAC monitoring, assessment of
baseline levels of these assays before DOAC treatment is beneficial and aids in
determining the effects of possible interference of the DOAC. A single assay to
detect the anticoagulant effects of all the DOACs would be an optimal strategy.
The previously mentioned diluted prothrombin time and Fiix-PT-assay (a PT
with only factors II and X deficient in the test plasma) are promising. However,
both require rigorous validation before routine clinical use.180 POC assays
might also be of use, since the dilution step in the PT and APTT assays is
omitted, leading to increased sensitivities to DOAC effects.160
Coagulation time testing alone is not comprehensive, even if drug-
calibrated methods or other specific methods are available. TG assay measures
the full spectrum of thrombin formation. However, even the semiautomated
CAT® is labour intensive with no random-access option for samples. This
requires sample batching, which is not always possible with urgent samples.
This is the main reason this assay remains mostly in research use. Recent
developments enabling TG measurement in whole blood also provides exciting
possibilities for future research with DOACs.148
The challenge with the DOACs is the same as is with coagulation in general.
A variety of factors need to be taken into account and no single variable alone
is sufficient. The future of DOACs looks promising, with many patients
benefiting from simple dosing. Lack of routine coagulation monitoring might
improve adherence.220 The role of the clinician is to offer the alternatives best
suited to the individual patient, with adequate support from the laboratory to




The effects of dabigatran, rivaroxaban and apixaban on laboratory assays
depend both on the characteristics of the assays as well as the individual
coagulation  status  of  the  patient.  We  have  shown  that  a  large  variety  of
different analysers and methods are currently available for basic coagulation
tests in European laboratories. It is therefore not trivial to undertake methods
for the assessment of DOACs on a wider scale.
Even if the concentration of the drug is known (functional assays dTT or
drug-calibrated anti-Xa assays most commonly used, or via the gold standard
method LC-MS/MS), it should be noted that there is more to coagulation in
patients on anticoagulation therapy than the concentration of the DOAC. For
example, with dabigatran, a paradoxical increase in TG was observed in
patient samples but not in spiked samples. The relevance of this observation
in patient treatment is not clear, as it is unknown at which conditions the
finding observed in the TG assay would materialise in the patient setting.
Standard dosing is recommended for all the DOACs. However, it is known
that the plasma concentrations in different patients vary widely. A statistical
approach in large randomised controlled trials means that if the majority gains
benefit, the drug is considered beneficial. A valid question is what would the
individual safety profile of a DOAC be in an individual patient who has very
high or very low plasma levels of the anticoagulant? We observed several-fold
differences in plasma concentrations between patients using rivaroxaban and
apixaban for thromboprophylaxis after orthopaedic surgery. Indeed,
alarmingly, there were patients in whom the drug concentrations were
undetectable at trough levels, even though the peak levels were measurable,
excluding non-compliance.
In conclusion, much is known and specific tests are available to assess the
DOAC levels in patients. With clinical experience and further studies, it might
be feasible to establish recommended drug concentration levels for patients in
treatment. With the development of new assays, it might be possible to assess
TG as a global assay in the clinical context. This would be an invaluable tool in
the assessment of thrombosis and bleeding risks, with applicability in all
DOACs.
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